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ABSTRACT

Every year, one-third of the 4 million child-bearing women in the United States
have a cesarean delivery. Of these, 91% have a repeat cesarean delivery with the birth of
subsequent children. Cesarean deliveries account for more than half of childbirth-related
hospitalization expenses totaling approximately $8 billion every year. A repeat cesarean
delivery has a 40% greater hospital cost than a vaginal delivery. Yet, the cost of the
delivery for the health-care payer is rarely addressed in the published peer-reviewed
literature.
The purpose of this research was to determine the cost-effectiveness of elective
repeat cesarean deliveries (ERCD) compared with trials of labor (TOL) in low-risk
women who had a cesarean delivery with their first pregnancy and are now in their
second pregnancy. The study compared the cost-effectiveness of ERCD versus TOL
from the perspective of the health-care payer (defined as private insurance, self-pay,
Medicaid, and Medicare). Cost-effectiveness was calculated on the difference of costs to
the health-care payer for a delivery-related hospital stay and the possible complications
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incurred by the mother and baby divided by the difference of length of stay in the hospital
for mother and baby for the two interventions, ERCD and TOL. Sources of data for the
study were the Agency for Healthcare Research and Quality’s (AHRQ’s) Healthcare Cost
and Utilization Project (HCUPnet) for the year 2010, and the peer-reviewed literature.
The study’s findings reveal that a TOL is more cost-effective than an ERCD, with a
possibility of cutting the health-care payers’ costs overall by $225 million per year.
Limitations of the study pertain to HCUP data, cost-effectiveness analysis assumptions,
physician idiosyncratic coding practices, and the effectiveness measure (LOS). The
findings have implications for practice, research, and policy. In particular, the findings
could be of interest to health-care providers counseling women about their choice for
mode of delivery, policymakers interested in creating new systems that reduce healthcare costs and increase patient engagement, and for researchers studying health-care
payment reform.
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Chapter 1
Introduction
One of the most important decisions in maternity care is determining the optimum
mode of delivery for a woman in her second pregnancy when her first resulted in a
cesarean delivery. Health-care providers customarily frame this choice to women as
balanced decision-making that considers the clinical risks and benefits between an
elective repeat cesarean delivery (ERCD) and a trial of labor (TOL). The principal focus
of this decision is on quantifying the likelihood of uterine rupture and the probability of a
vaginal delivery. A second pregnancy after a cesarean delivery presents a unique
opportunity for a woman to be offered a choice between a planned vaginal or planned
cesarean birth. The American College of Obstetricians and Gynecologists (ACOG, 2004)
addressed this choice in a practice bulletin regarding vaginal birth after cesarean (VBAC)
by endorsing the concept of including the woman’s preferences and values in the clinical
decision-making. ACOG concluded that the decision between ERCD and an attempt at a
TOL should ultimately be made through a collaborative exchange between the physician
and the patient after thorough counseling on risks and benefits and consideration of the
woman’s preferences and values.
Within the context of delivery after cesarean, Kamal and Kupperman (2010)
conducted a review of the literature on methods of communicating risks and benefits,
provider and patient preferences, and obstetrical decision-making. Their review
concluded that gaps in research on these topics remain, which, if filled, could contribute
to development of a framework with important information for a woman when forming
her preferences for either ERCD or TOL.
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First, it is necessary to identify the types of data that are essential for a woman
when formulating her preference for an ERCD versus TOL. Emmett, Shaw,
Montgomery, and Murphy (2006) interviewed 21 women in England about their views on
decision-making for their childbirth. These women had all recently given birth via
cesarean delivery. The researchers concluded that women whose previous pregnancy had
resulted in a cesarean delivery wanted more information on clinical risks and benefits,
and economic information such as costs, when using shared decision-making about mode
of delivery. Emmett et al. (2007) piloted a computer-based decision aid that incorporated
economic considerations, including direct costs of hospitalization, and reported that many
of the 21 participants found the decision aid helpful and had less decisional conflict when
economic information was included.
In the peer-reviewed medical literature, economic considerations have generally
been approached through various types of economic analyses: cost-minimization analysis
assumes equal outcomes; cost-effectiveness analysis measures cost per unit of
effectiveness with the effectiveness measure in clinical units; cost-utility analysis is
usually measured in quality adjusted life years; and cost-benefit analysis is measured by
outcomes in dollars (Rascati, 2009).
Much of the current published literature related to cesarean deliveries focuses on
safety, demographics, geographic differences, and clinical management issues
(Cunningham et al., 2010; Guise et al., 2010). Little has been published on the overall
economic consequences of ERCD. Peer-reviewed articles describe a few studies on the
economic consequences of repeat cesarean deliveries compared to TOL from the
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perspectives of the health-care payer or the woman and her family (Chung et al., 2001;
DiMaio, Edwards, Euliano, Treloar, & Cruz, 2002; Grobman et al., 2000).
Clark et al. (2000), Chung et al. (2001), and Macario, El-Sayed, and Druzin
(2004) used a hypothetical population to perform their cost-effectiveness analyses of
TOL compared with ERCD. All three of the research teams concluded that a TOL, when
a vaginal delivery without complications was successfully achieved, was more costeffective than an ERCD. They also reported that if the TOL resulted in a cesarean
section, the direct cost of hospitalization would be greater by thousands of dollars than
with an ERCD or TOL because of a longer hospital stay and documented complications.
DiMaio et al. (2002) and Grobman et al. (2000) performed cost-effectiveness
analyses comparing ERCD and TOL. DiMaio et al. (2002) reviewed 204 medical records
in a retrospective cost-effectiveness analysis. They included the medical records of all
women who delivered at their hospital in Florida in 1999 and had a history of one
previous cesarean delivery prior to admission. They found a TOL to be more costeffective than an ERCD; their primary outcome variable was the mean cost of hospital
care in their own hospital. Grobman et al. (2000) used a decision tree to analyze the
reproductive life of a hypothetical cohort of 100,000 women with a history of cesarean
deliveries, they included in their analyses the cost of a second delivery, whether ERCD or
TOL. Their robust analysis showed an increase in maternal mortality, morbidity, and cost
with ERCD. This led them to conclude that a TOL resulting in a vaginal delivery was
more cost effective by thousands of dollars than an ERCD. Their outcome variable was
the overall cost of maternal and neonatal morbidity and mortality in their health-care
system.
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The perspective, an economic term that describes whose costs are relevant based
on the purpose of the study, varied in these studies. Chung et al. (2000) and Macario et
al. (2004) considered the broad allocation of resources affected by the decision made in
the second pregnancy in the context of planned vaginal or cesarean delivery. This is
referred to as the societal perspective, which includes a comprehensive view of the costs
(direct and indirect) experienced by all those affected by the studied intervention. Clark et
al. (2000) and DiMaio et al. (2004) performed their cost-effectiveness analysis from a
health-care system’s perspective. Grobman et al. (2000) used the perspective of a healthcare provider using data from a specific hospital in Florida.
Definitions of terms are useful in economic analyses. The health-care payer is an
organization or entity that purchases or pays for services given to a group or individual
(Tampor & Mohr, 2014). For the purpose of this study, the term health-care payer
encompasses private insurance (of all types), Medicaid, Medicare, and self-payment by
an individual (Health Care Utilization Project, 2010). A health-care system is the
organization that provides health related services, and then bills the health-care payer for
those services. The health-care payer’s perspective is broader than that of one health-care
system, which means it could be more generalizable. To date, there is no evidence of
work reported by other researchers regarding cost-effectiveness for ERCD and TOL in a
second pregnancy and the possible complications of each to the mother and baby from
the perspective of the health-care payer.
The major goal of the Patient Protection and Affordable Care Act (2010) (here
after referred to as the ACA) is to ensure that everyone receives as high quality health
care as possible at an affordable cost (Catalyst for Payment Reform, 2013). Many

5
provisions of the ACA (2010; Kaiser Family Foundation, n.d.) affect health-care payers.
A major challenge for health-care payers is improve population and patient outcomes
while maintaining or lowering costs. In an effort to manage their costs, health-care payers
often require consumers to assume a greater share of their health-care costs. To
accomplish this, payers recognize that consumers need more information on the cost of
health care. With knowledge about health-care costs, the ability of payers and consumers
to make effective decisions is enhanced. This cost transparency for health-care payers
and consumers could help payers contain costs, inform consumers’ health-care decisions
as they take on a greater financial responsibility, and reduce price variations (Catalyst of
Payment Reform, 2013).
Cesarean deliveries are the most common surgical procedure in the United States,
totaling 1.5 million childbearing women in 2010 (Guise et al., 2010). Guise et al. (2010)
used an evidence-based approach to perform a systematic review of 3,134 citations and
reviewed 963 papers. Of those, 203 met the inclusion criteria, finding prior cesarean
delivery as the most common indication for a cesarean, accounting for more than onethird of cesarean deliveries a year. In 2007, Guise et al. (2010) also noted that 8.7% of
childbirth-related hospital admissions among women with previous cesarean deliveries
were attributed to VBAC. A major finding of their report, using an evidence-based
approach, showed TOL to be a reasonable choice for women. Guise et al., however,
noted the lack of data on cost-effectiveness, specifically what it costs the health-care
payer for a woman’s choice between an ERCD and TOL. This study may fill that gap by
providing a cost-effectiveness analysis of the different choices for modes of delivery after
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cesarean from the perspective of the health-care payer. The major outcome variables are
length of hospital stays for the mother and baby.
Statement of the problem
Every year, one-third of the 4 million childbearing women in the United States
have a cesarean delivery (Guise et al., 2010). Of these, 91% have a repeat cesarean
delivery with the birth of subsequent children (Menacker, Declercq, & Macdorman,
2006). Annual U.S. cesarean delivery rates increased from 4.5% in 1965 (when they were
first recorded) to a high of 32.9% in 2009 (National Center for Health Statistics, 2011).
Many repeat cesarean deliveries are elective, meaning that women who previously
underwent a cesarean delivery for medical reasons opt for the procedure when given a
choice between a cesarean and a vaginal delivery for a subsequent birth. From 1997 to
2007, ERCD increased by 19%, from 72% in 1997 to 91% in 2007 (U.S. Department of
Health and Human Services [USDHHS], 2012).
One of the goals of Healthy People 2010 (USDHHS, 2012) was to decrease the
United States’ cesarean delivery rate to 15%. As 2010 has come and gone, the rate, 32%,
is still more than twice that goal (Guise et al., 2010). Healthy People 2020 (USDHHS,
2011) has a revised goal for reducing the cesarean delivery rate than Healthy People
2010. It aims to decrease the overall rate by 10% (from 32.9% to 22.9%). This includes
primary cesarean and repeat cesarean rates (USDHHS, 2011).
Clinical researchers have offered several possible explanations for the growth
rates of cesarean deliveries. These include the increase in multiple births due to fertility
treatments (Reynolds, Schieve, Martin, Jeng, & Macaluso, 2003), maternal request
(particularly because of the rising age of parturition) (Lee & D’Alton, 2008), providers’
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fears of litigation (Brown, 2007; Minkoff, 2012), maternal fear of urinary incontinence
(Wax, Cartin, Pinette, & Blackstone, 2004), and increasing physician reimbursement
rates for cesarean deliveries (Grant, 2009).
Cesarean deliveries account for more than half of all U.S. childbirth-related
hospitalization expenses totaling approximately $8 billion annually (Guise et al., 2010).
Although the Agency for Healthcare Research and Quality (AHRQ, 2009) reported that a
repeat cesarean delivery has a 40% greater hospital cost than a vaginal delivery, the cost
of the delivery for the health-care payer is rarely addressed in the published peerreviewed literature. Moreover, few researchers have analyzed the cost-effectiveness of
cesarean deliveries compared to vaginal deliveries for a second pregnancy from the
perspective of the health-care payer, despite the growing proportion of childbirth-related
hospitalizations and significant cost to the health-care delivery systems.
When reviewing recent published literature related to cesarean deliveries,
emphasis is on safety, demographics, geographical differences, and clinical management
issues, but few published studies analyze the economic consequences of ERCD
(Cunningham et al., 2010). Peer-reviewed articles and government reports refer to a few
studies on such deliveries compared to a TOL from the perspective of the health-care
system (Clark et al., 2000; DiMaio et al., 2003), health-care provider (Grobman et al.,
2000), or the woman and her family (Chung et al., 2001; Macario et al., 2004).
Health economists have used cost-effectiveness analyses to compare costs of two
or more interventions and their expected gains for a specific population (Gold, Siegel,
Russell, & Weinstein, 1996; Rascati, 2009). In the present study, a systematic review of
the nursing, medical, public health, and economics literature was conducted from 2000 to
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2010, to identify published cost-effectiveness studies as they relate to ERCD versus TOL.
Most of the literature on cost-effectiveness analysis in this area compares ERCD with the
choice of a TOL (DiMaio et al., 2002; Grobman et al., 2000; Macario et al., 2004). Only
a couple of studies (Clark et al., 2002; Chung et al., 2000) have reported evidence
regarding the cost per unit of clinical effect for the target population of concern here—
those women electing repeat cesarean deliveries compared to women electing to attempt
a vaginal birth after a previous cesarean delivery.
Chung et al. (2001) performed a cost-effectiveness analysis using a hypothetical
computerized model of a 30-year-old woman’s choices for her mode of second delivery
after having a cesarean with the first pregnancy. The objective was to determine which
mode of delivery, ERCD or TOL, was most cost-effective. The model employed by
Chung et al. used data from peer-reviewed studies, actual hospital costs from 1999, and
utilities (a preference measure) to quantify health-related quality of life. Their
incremental cost-effectiveness model compared the additional cost that one intervention
incurred over the other, with health-related quality of life as their outcome measure.
Chung et al. concluded that if the probability of successful vaginal delivery was between
0.74 and 0.76, a TOL that resulted in an uncomplicated vaginal delivery was more costeffective than either an ERCD or a rescue cesarean delivery (RCD). Hospital costs were
from one state, Florida, limiting national generalizability.
Given the scarcity of empirical studies that compare the cost-effectiveness of
ERCD with TOL, a cost-effectiveness analysis from the perspective of the health-care
payer is both relevant and necessary. This study uses the methodology of the Chung et al.
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(2001) study as a guide, combined with current (2010), nationally representative cost data
and event probabilities.
Moreover, this method has several cost implications. For example, the average
length of stay for childbirth-related hospitalizations is 2.8–3.5 days (Guise et al., 2010).
Each additional day of care needed for a complication adds to the overall cost of
hospitalization. Furthermore, knowing that total charges are over 40% higher for a repeat
cesarean delivery than for a TOL, a cost-effectiveness analysis from the viewpoint of the
health-care payer could offer information to help women and providers in determining
the optimum mode of delivery for women in their second pregnancy when their first
resulted in a cesarean delivery (AHRQ, 2009).
If this economic analysis determines that an uncomplicated TOL is more costeffective than an ERCD, then health-care payers could suggest a new formulation for
maternity payment, such as a bundled rate (all care paid in one payment) for maternity
care instead of paying fee-for-service to providers and hospitals separately. Having
evidence of cost-effectiveness might inform and even change the decision faced by
women and their providers (ERCD vs. TOL), which may lead to better outcomes for
mothers and babies and lower costs overall to health-care systems. The potential findings
of cost-effectiveness for one strategy over the other resulting from this study would again
provide only one piece of evidence as this decision is multifaceted, entailing mother’s
preferences, provider liability, and provider reimbursement.
Statement of Purpose
The purpose of this research was to determine whether an ERCD is cost-effective
when compared to a TOL at term (in a second pregnancy) from the perspective of the
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health-care payer. Decisional analysis was used to model the decision made by a woman
in her second pregnancy after her first pregnancy resulted in a cesarean birth and to
determine the cost-effectiveness of the decision.
Research Objectives
This study’s research objectives were:
1. Establish the probabilities of complications incurred by mother and baby for
ERCD and TOL in a second pregnancy.
2. From the perspective of the payer, determine the costs associated with ERCD
and TOL by the mother and the baby in a second pregnancy.
From the perspective of the payer, determine the outcomes (length of stay)
associated with ERCD and TOL by the mother and the baby in a second
pregnancy.
3. Determine and calculate an incremental cost-effectiveness ratio for ERCD and
TOL for mother and baby in the second pregnancy.
Note: Lists of definitions and abbreviations are in Appendices A and B, respectively.
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Chapter 2
Literature Review
This chapter provides a review of the literature in three major areas: (a) the
clinical question of choice of mode of delivery, the controversy over choices between
costs of TOL and ERCD with a second pregnancy, from health-care payer’s perspective,
and point of service payment reform; (b) the framework of economic evaluations in
medicine; and (c) previous economic studies performed around VBAC or TOL compared
to ERCD in a second pregnancy.
Pregnancy and Maternity Care
Pregnancy and birth of a child are unique experiences for each woman. Women
and their families maintain different views and preferences about childbearing based on
their values, knowledge, belief systems, culture, and social backgrounds (Mortimer et al.,
1990). The goal of maternity care is to promote evidence-based, safe, effective, timely,
efficient, and equitable care promoting optimal health outcomes for the mother and baby
(Cunningham et al., 2010; Varney, Kriebs & Gegor, 2004). Maternity care represents an
opportunity to promote and improve health through teaching health promotion and
disease prevention, including nutrition counseling and weight management. The majority
of women seeking prenatal care have private insurance (51%) an additional 42% are
covered by Medicaid programs (Sakala & Corry, 2008). Many other women without
health insurance begin receiving health insurance benefits (private insurance or
Medicaid) in the early portion of their pregnancy by applying for maternity coverage.
Maternity care practices impact outcomes for mothers and babies while
attempting to minimize the risk of harm. Effective maternity care is meant to minimize
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overuse, underuse, and misuse of care practices and services (Institute of Medicine,
2001). It is also important that maternity care be timely, which means that care is
delivered when it is needed. Timely maternity care is determined by maternal-fetal
physiology, not by external time pressures without clear medical indications. Efficient
care produces the best possible health outcomes using the most appropriate and
conservative application of resources and technology (Institute of Medicine, 2001).
Equitable care means all women and their babies have access to and receive high-quality
and high-value care. Variations in maternity care should only be based on the health
needs and values of each woman and her baby, not on other nonmedical factors (Institute
of Medicine, 2001).
Sakala and Corry (2008) list the essential features of prenatal care as being
evidence-based and supportive for decision-making, and choices, for example, genetic
testing and delivery setting. These concepts together entail providing information about
risks and benefits, harms, and areas of uncertainty in the care being offered. An
interactive process that takes place between a woman and her care provider is built into
maternity care at every level (Mortimer et al., 1990; Varney, Kriebs, & Gegor, 2004).
During this interactive process, the provider offers information, taking into consideration
the woman’s values and preferences, including the desired level of involvement from her
family, in language that is appropriate and understandable, and gives her time to process
the information. Making an informed choice about maternity care means that women
have access to the full range of safe and effective care options, and take into account care
givers’ opinions, care setting, and their family’s choices and preferences. A woman
ideally has the essential choice about options, including the mode of her delivery.
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Mode of Delivery for First Pregnancy
At term (39 weeks gestation or greater) with a first pregnancy, a woman has many
choices to face. She has most likely chosen her delivery setting and care provider. In
2010, almost 4 million women gave birth (Martin, Hamilton, Ventura, Osterman &
Mathews et al., 2012). The first-birth rate was 25.9/1000 women, which was down 3%
from 2009 (Martin et al., 2012). The majority of women chose to deliver with a physician
(86.3%) or a certified nurse midwife (CNM, 7.6%) in a hospital (Martin et al., 2012).
Although most women still elect to have a vaginal delivery, recently decisions
made by patients and their providers have shifted toward cesarean delivery by maternal
request. In 2006, approximately 2.5% of all births in United States were cesarean
deliveries by maternal request (Lee & D’Alton, 2008). This decision (by maternal
request) is typically made knowing there are no medical indications for this procedure.
Most often cesarean delivery by maternal request happens with a first pregnancy. Lee and
D’Alton (2008) listed as advantages of cesarean by maternal request (a) avoiding an
emergent or unplanned cesarean, which carries a much higher risk for morbidity, (b)
convenience of planning the day of delivery, (c) lower risk of hemorrhage than with an
emergent cesarean delivery, and (d) lower in neonatal neurologic injury compared to an
emergent cesarean delivery.
The disadvantages of cesarean by maternal request are (a) a pregnancy after a
prior cesarean have a higher incidence of abnormal placental implantation, such as
placenta previa or acreta, (b) higher possibility of uterine rupture in pregnancy after prior
cesarean, and (c) future pregnancies need to be limited to one or two planned cesareans.
Although neonatal respiratory morbidity is higher with cesareans and the woman’s future
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pregnancy might have abnormal placental implantation, most obstetricians are following
ACOG Committee Opinion No.394 (2007b), which addresses decision-making that
allows women to have primary elective cesarean deliveries, and honors the woman’s
request.
A woman has a low risk of pregnancy complications if she has completed 38
weeks of pregnancy, has one fetus whose head is down, and has not had any obstetric or
medical complications in the pregnancy (Kamath, Todd, Glazner, Lezotte, & Lynch,
2009; Tita et al., 2010). One-third of the normal low-risk first pregnancies result in
cesarean deliveries (Zhang et al., 2010). Indications for nulliparous women to have a
cesarean delivery are failure to progress (47.1%), nonreassuring fetal heart rate or fetal
distress (27.3%), fetal malpresentation (7.5%), hypertension (1.6%), and fetal
macrosomia (1.2%) (Zhang et al, 2010).
Zhang et al. (2010) grouped indications for cesareans as clinically indicated
(74.9%), done for mixed reasons (11%), and truly elective (2.5%). Kennare, Tucker,
Heard, and Chan (2007) included additional indications for cesarean deliveries as
antepartum bleeding (2.75%), intrauterine growth retardation (1.3%), and other (10.8%),
encompassing herpes and HIV. Zhang et al. also showed a two-fold increase in a
woman’s labor resulting in a cesarean if she was induced. Kennare et al. suggested two
approaches to decrease the overall cesarean rate: a) was to cut down the number of the
primary cesarean deliveries, which account for 40% of first births, and b) decrease the
number of women induced with an unfavorable cervix.
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Clinical Decision-Making
For most of the 20th century, providers thought that once a woman had a cesarean
delivery, all her future pregnancies would end the same way (Guise et al., 2010). In 1980,
the National Institutes of Health (n.d.) held a Consensus Development Conference:
Vaginal Delivery after Cesarean to study two questions: (a) Does a previous cesarean
delivery necessitate a repeat cesarean delivery? and (b) In what situations might a vaginal
birth after cesarean be a clinically feasible option? The consensus conference participants
concluded that VBAC was a viable option. This conclusion contributed to an increase in
the number of VBACs from 18 per 100 live births in 1980 to about 30 per 100 live births
in 1996 (National Center for Health Statistics, 2007). As the rate of VBACs increased,
researchers noted a rise in the risk of uterine rupture (Grobman et al., 2008). Starting in
the mid-1990s, the cesarean delivery rate overall increased and as of 2012 is at an alltime high of 32.9%. At the same time, the rates of VBACs started to drop and as of 2010
were at 9% (Cunningham et al., 2010).
The increase of cesarean deliveries and the decrease of VBACs are thought to
have occurred for both clinical and nonclinical reasons (Cunningham et al., 2010). One
clinical reason is the increased number of uterine ruptures with VBACs (Grobman et al.,
2008). The nonclinical reasons include providers’ interpretation of the American College
of Obstetricians and Gynecologists (ACOG, 2010) guideline requiring an obstetrician to
be “immediately” available during a TOL because of a known high risk of complications
if a TOL is unsuccessful and a perceived increase in uterine rupture rate. Because of
medical-legal concerns, many obstetricians and hospitals have impeded full choice for
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VBAC, citing that they could not provide “immediate” availability of anesthesia and
obstetricians (Bucklin, 2003).
In 2010, the NIH (n.d.) convened the Consensus Development Conference:
Vaginal Birth after Cesarean, which was a summit of leaders in women’s health
interested in reaching a consensus on VBAC. Using an evidence-based approach,
including a meta-analysis of the medical literature (Guise et al., 2010), the attendees
deemed “a TOL a reasonable option for many pregnant women with one prior low
transverse uterine incision” (Cunningham et al., 2010, p. 2). This evidence-based
consensus statement was aimed at enhancing obstetrical stakeholders’ understanding of
the clinical risks and benefits of VBACs, their interactions with nonclinical factors, and
their potential impact on informed decision-making.
Informed decision-making was one of the non-clinical factors that participants at
both the 1980 and 2010 summits discussed. Bekker et al. (1999) defined informed
decision-making as a process in which “a reasoned choice is made by a reasonable
individual using relevant information about the advantages and disadvantages of all
possible courses of action, in accord with the individual’s beliefs” (p. 1). The term
informed decision-making emerged partly with the rise in advocacy organizations
placing pressure on the health-care administrators in health-care systems to help
consumers assess the appropriateness of recommended cancer screening tests such as
mammograms, pap smears, prostate screening, clinical breast exams and colorectal
screening (Rimer, Briss, Zeller, Chan, & Woolf, 2004). Consumer groups and researchers
have given much attention to using informed decision-making with breast cancer
treatments (Bekker et al., 1999; Rimer et al., 2004). The essential components of
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informed decision-making are (a) understanding the screening test (or procedure) and its
risks, benefits and alternatives; (b) understanding personal values and preferences; (c)
considering pros and cons of a test (or procedure); (d) discussing decisional preferences
and seeking additional information; and (e) deciding on a plan of action (Bekker et al.,
1999; Rimer et al., 2004).
Reviewing the risks and benefits of a TOL and repeat cesarean delivery with the
mother may have a significant impact on her ability to make an informed choice.
Chervenak and McCullough (2011) contended that the key component of informed
decision-making is a “reliable account of benefits and harms relevant to the care of
patients and of how those goods and harms should be reasonably balanced against each
other” (p. 28). Additionally, Chervenak and McCullough suggested that recognizing the
woman’s knowledge level (taking into account how the general public understands the
baseline risk of childbirth) and considering the impact of the provider’s delivery of
information are practices that should be incorporated into informed decision-making.
Murray, Charles, and Gafni (2006) conceptualized informed consent as a process
in which information is transferred in a reciprocal manner, with both the patient and
provider using their expertise. The health-care provider is the expert in options of
treatment, and the patient is the expert in her own circumstances and preferences of
treatment outcomes. As values are shared, the treatment deliberation becomes a joint
decision, taking into consideration various treatment options, provider priorities, and
patient preferences. Entwistle and Watt (2006) cited evidence showing that when patients
had a sense of involvement with decision-making, it had positive implications for their
health status.
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In their development of shared decision-making approaches, Charles, Gafni, and
Whelan (1997), acknowledged that one method of informed consent is not best for every
encounter. How do providers switch from the paternalistic model of informed consent
they learned while in their professional education training for medical, nursing, or
physician assistant to a shared decision-making process, while still respecting both the
patient’s preferences and their own beneficence? Leclercq, Kulers, Scheltinga, Spauwen,
and van der Wilt (2010) claimed that with an increase in the complexity of surgical
operations and the pressure of patients wanting to know more about their options, the use
of computer-based information as part of shared decision-making could meet the needs of
both providers and patients. They contended that although retraining health-care
providers is costly in time and money, using computer-based educational materials does
not necessarily undermine the clinician/patient relationship, but instead can enhance it.
Informed decision-making is closely related to shared decision-making. The latter
connotes a process where the provider and patient share in the decision-making process
usually in face-to-face encounters (Rimer et al., 2004). In maternity care, shift from
informed decision-making to sharing the decision with the woman moves the
conversation and decision from the “paternalistic” manner of telling a patient what
treatment to have to involving the patient in making decisions about her health care
(Makoul & Clayman, 2006). Godolphin (2009) noted that patient-centered care is a key
element in improving quality and safety in health care. He contends that many errors can
be avoided by having more active patient involvement. Shared decision-making, as a best
practice in patient-centered care, was recommended in the Institute of Medicine’s (2001)
landmark report Crossing the Quality Chasm: A New Health System for the 21st Century.
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The report concluded that, “the best care results from the conscientious, explicit, and
judicious use of current best evidence and knowledge of patient values by well-trained,
experienced clinicians” (p. 76). Towle, Godolphin, Grams & LaMarre (2006) contended
that putting this new paradigm into practice is an ethical imperative. It modifies the
present system from “paternalism” with the provider, who is the expert in medicine,
holding the monopoly of power, to a shared decision with the patient, who is an expert in
his/her own life, values and circumstance.
Changing the dynamics of the relationship between provider and patient will
entail educating both groups, especially by letting patients know their preferences and
values matter as much as the evidence-based options provided by clinicians (Declercq,
Sakala, Corry, & Applebaum, 2006). Shared decision-making is used in many health-care
decisions with reasonable paths to choose, from the option of doing nothing (when
appropriate) to choosing different therapies leading to possibly differing outcomes.
Examples of conditions for which shared decision-making has been used include breast
cancer, prostate cancer, lipid-lowering medications for prevention of cardiac disease, and
genetic and cancer screening (Barry & Edgman-Levitan, 2012).
Many guidelines written for providers in obstetrics by ACOG have changed in the
past 10 years. The present recommendation for shared decision-making from the 2010
NIH consensus report and ACOG is to allow a woman a choice with adequate counseling
on risks and benefits for a TOL or ERCD. Eden et al. (2010) evaluated screening tools
with the goal of establishing a method of prediction for successful VBAC versus a failed
attempt; however, they did not find an adequate method. Grobman et al. (2011), also
looking for a way to predict who will be successful, concluded in their analysis that
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VBACs are decreasing because fewer women and their providers are seeking a TOL.
Their goal was “to provide insight into whether changes in the choice of undergoing a
TOL or the abandoning of a TOL are related to the changes in a population’s
characteristics or to the approach to patient care” (p.41).
The 2010 NIH consensus report strongly recommended a greater use of shared
decision-making as a necessary change in the approach to VBAC, which could affect the
rate of VBACs. Preference-sensitive shared decision-making strives to balance the best
available evidence-based knowledge about treatment options, including risks and benefits
offered by the provider, with the patient’s values and preferences. Together, the patient
and the clinician deliberate about options and come to a consensus that considers
advantages and disadvantages (including no treatment). This consensus is a joint
decision, taking into consideration advantages and disadvantages and concluding with a
plan both patient and provider is willing and able to implement (Makoul & Clayman,
2006).
Contextual conditions are important to include in shared decision-making (Towle,
Godolphin, Grams, & LaMarre, 2006). For instance: Are patients able to make their own
decisions (were they recently medicated for pain)? Do they have the education level or
ability to understand the conversation? Is the conversation in their native language?
Towle et al. (2006) counseled and trained family physicians to implement shared
decision-making and found it was difficult for physicians to change how they offer
information and consider patient’s preferences, though they agreed with the overall
concept.
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For many reasons, it has been difficult to engage providers in implementing
shared decision-making (Elwyn et al., 2010). Lagaré et al. (2008) found that health
professionals self-selected patients for whom they deemed shared decision-making was
feasible and functional. This practice did not allow for patient involvement in decisionmaking. Elwyn et al. contended that the use of high quality decision aids is a best
practice to encourage patient and provider engagement in shared decision-making.
Using shared decision-making with a woman during her maternity care is an
opportunity for a health-care provider to be the expert in medicine and partner of the
patient, who is the expert on her values, life history, and preferences. However, shared
decision-making is not widely utilized, happening in about 10% of medical encounters
(Godolphin, 2009). Towle et al. (2006) formulated an educational plan for physicians to
use shared decision-making in their practices. Though many physicians agreed with the
key characteristics of implementing this practice, few followed their training, citing that it
took too much time (Towle, et al., 2006). Patients do not expect shared decision-making.
Some do not understand the medical terminology used, and others contend that being
assertive in a medical encounter might affect their relationship with their provider (Stacy
et al., 2011). Others rely on the physician as the expert, and their own opinions and
preferences do not matter to them.
To enhance the effectiveness of shared decision-making, researchers, patients, and
clinicians have called for changes in the provider-patient relationship. A conversation
rooted in a relationship between informed patients and benevolent providers moves the
process away from paternalism (Godolphin, 2009). Laws and professional guidelines
increasingly encompass consenting processes, which are gradually raising the use of
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shared decision-making. Furthermore, medical education is now expanding training in
communication skills, including shared decision-making. Decision aids are being
developed to aid patients and providers with a range of information considering the
patient’s values and the provider’s evidence with the ultimate goal being improved health
outcomes (Leclercq et al., 2010; Stacy et al., 2011).
Shared Decision-Making Regarding ERCD and TOL
Six issues surface when reviewing the literature on shared decision-making and
ERCD and TOL. The first four have bioethical considerations that include (a) respect for
a woman’s autonomy, which governs her right to choose or refuse recommended
treatments for herself and her fetus; (b) the provider’s beneficence, meaning that the
provider has the obligation to promote the health and well-being of the woman and fetus;
(c) conflicts between respect for autonomy and beneficence; and (d) social justice, the
same manner of shared decision-making being offered to all women, so that the great
majority have a choice and are not being put at clinical risk (Sharma, Chervenak,
McCullough, & Minkoff, 2004). The other two issues pertain to access to care and other
controversies surrounding access to ERCD versus TOL.
Respect for a woman’s autonomy. Autonomy is defined as self-governance or
“self-rule that is free from a controlling interference by others and limitations that prevent
meaningful choice” (Beauchamp & Childress, 2013, p. 101). With regard to maternity
care, autonomy means that a woman has the freedom to make an informed decision about
the mode of delivery of her baby. Her decision will be influenced by her understanding of
the spectrum of risks and benefits of a TOL and ERCD, whether she has been given the
evidence to support these risks and benefits, and whether the delivery setting affords her
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those choices. In paternalistic informed consent (e.g., “I think this is best for you”), the
provider gives her the information he or she thinks the woman needs and essentially tells
her how she will deliver (Sharma et al., 2004). With shared decision-making, the healthcare providers’ present information in a manner that gives the evidence of the risks and
benefits, describes the possible complications, answers questions, and supports the
woman in her decision, even if the clinician does not agree (Sharma et al., 2004).
Research on perceived consent (how patients perceive the process through which
they are consented to a procedure) is limited, but the concept is important to understand
in relation to shared decision-making. The major study on perceived consent found that
26% of women surveyed (national sample of 200 patients by phone and 1,373 by online
questionnaire) who had a previous cesarean birth, felt pressured by the provider to have
another cesarean (Declercq, Sakala, Corry, & Applebaum, 2006). In addition, whereas
81% felt all complications should be disclosed during the discussion, 10% of these
women did not feel that had happened in their case. When asked who should make
decisions about the mode of delivery, 73% stated that the woman, after consulting with
the provider, should make the decision, barring no medical complication that would make
the situation emergent. A very small portion (3%) felt the provider should make the
decision after talking to the woman. In general, all respondents felt that providers should
not be the sole decision-maker.
Bernstein, Matalon-Grazi, & Rosenn (2012) also looked at patients’ perceptions
of informed consent for ERCD and TOL. This group performed a prospective study of
155 women presenting to their hospital with a second pregnancy who were candidates for
a TOL. Upon admission for their ERCD or TOL, the women filled out a questionnaire
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about their perceptions of informed consent. The results from this questionnaire
demonstrated a lack of knowledge about the risks and benefits of the chosen procedure
for women electing for both ERCD or for TOL. This study also revealed that patients
chose the procedure they perceived to be their provider’s preference.
Beauchamp and Childress (2013) contended that respect for autonomy obligates
the provider to disclose information and to probe for and ensure understanding with the
purpose of fostering proper decision-making. To respect an autonomous agent is to
recognize that person’s right to hold views, to make choices, and to form a plan of care
based on his or her values and beliefs (Beauchamp & Childress, 2013; Power & Faden,
2006).
Provider’s beneficence. Beneficence is defined as an act of kindness or doing
good, and a charitable gift (Beauchamp & Childress, 2013). Nonmaleficence is the
obligation to do no harm. Bioethicists and health policy scholars often conceptualize
these two words as manifestations of the same principle (ACOG, 2007a). This underlying
principle demands that while offering information on a choice of procedures (ERCD or
TOL), the provider should respect the woman’s autonomy while taking into consideration
the well-being of both the mother and baby (Sharma et al., 2004). Broad principles of
ethics require that beneficence and nonmaleficence be used together, especially when the
situation is complicated by the patient’s psychological makeup, physical condition, race,
education level, and spiritual well-being (Beauchamp & Childress, 2013). An example of
a situation where provider beneficence is particularly important is when a woman has had
a long labor, is exhausted and not progressing, and needs to make a decision about a
cesarean section.
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Conflicts between autonomy and beneficence or nonmaleficence. The
Hippocratic Oath, which all physicians take, is centered on beneficence and
nonmaleficence, “to help, or at least do no harm” (Beauchamp & Childress, 2013, p.
214). Traditionally, physicians have depended on their own judgments about their
patient’s desires for information about treatments and treatment choices. However, in the
world of modern medicine, patients increasingly need to receive information and make
independent judgments. Respect for autonomy comes into conflict with beneficence
when a patient disagrees with the recommendations a health-care provider considers to be
in the patient’s best interest. Examples would be a patient not wanting a treatment due to
cultural and religious beliefs or family members having differing opinions as to the
treatment plan (Beauchamp & Childress, 2013). In obstetrics, for example, a woman
might switch providers after being counseled about risks and benefits for ERCD versus
TOL if she realizes her values and beliefs are not being supported.
Social justice. Social justice is defined by Rawls (1971) in terms of equality and
liberty. Rawls claimed each member in society has an equal claim on the goods of
society. Beauchamp & Childress (2013) aligned their definition of justice to distributive
justice, which declares that vital social resources, including healthcare, be dispersed
according to need. This implies that individuals should receive equal treatment unless
medical evidence establishes relevant treatments that differ due to circumstances or
situations. Powers and Faden (2006) agreed that social justice for health policy
concentrates on inequalities in health and access to healthcare. In clinical practice, social
justice requires balancing clinicians’ obligation to render the care a patient is entitled to
with the allocation of limited resources. On a societal level, this becomes complicated by
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decisions regarding the allocation of scarce resources, such as some Medicaid programs
not reimbursing for organ transplants (Cappel, Phillips, & Phillips, 2011). On an
individual level, social justice might be compromised when a woman requesting an
attempt for a VBAC is not offered this choice because anesthesia for an emergency
cesarean delivery is not available (ACOG, 2007b), or when clinicians fail to offer shared
decision-making for a TOL because they are uncomfortable providing the procedure.
Denial of access. Clinicians often attribute the limitations to a woman's access to
a TOL following a previous cesarean delivery to guidelines in the ACOG Practice
Bulletin (ACOG, 2010), which state that immediate availability of a physician and
anesthesia is necessary to offer a TOL. This immediate response is necessary because an
existing uterine scar could cause the placenta to detach, causing maternal hemorrhage,
which could lead to hypoxia (decrease in oxygen) of the fetus. Hypoxia can cause fetal
brain injury or death if the baby is not delivered immediately. The national incidence of
uterine rupture for TOL is 4.7/1000 and for ERCD is 0.3/1000 (Guise et al., 2010). The
risk of uterine rupture occurring is thought to be the primary reason a TOL is not offered
in some communities (Cahill et al., 2006). ACOG’s “immediately available” clause has
created a group, or separate class, of patients that are not offered a vaginal birth after
cesarean because a physician or hospital is unable to provide an immediate (within 30
minutes) response for a rescue cesarean delivery. Roberts, Deutchman, Fryer, King, and
Miyoshi (2007) compared hospitals that continued providing VBACs with those that
stopped allowing them after the ACOG Practice Bulletin (2010) was published. They
determined that three out of every 10 hospitals (68 of 229 or 29.7%) that previously
allowed VBACs had discontinued the practice by 2005.

27
Controversy over choices. Approximately 40% of the 1.3 million cesarean
deliveries performed each year are scheduled elective repeat procedures (LydonRochelle, Cahill & Spong, 2010). Counseling for the choice between ERCD and TOL
varies (Declercq et al., 2006). For a woman, making this choice can feel like being
engaged in a controversy about what choices she has. This controversy centers on safety,
but the risks and benefits are not quantified in one place, making it difficult to find
information easily. Some delivery settings address the issue of safety by not offering a
TOL due to lack of necessary staff and availability in their facility for an emergency
delivery. Moreover, physicians may have reservations about proposing a TOL out of fear
of litigation, which might give women the feeling that all of their options are not being
offered to them (Brown, 2007; Minkoff, 2012).
ERCD, VBAC, and TOL
ACOG (2010) provides an overview of how to evaluate data presented in the
literature regarding the incidence of ERCD, VBAC, and complications from these
procedures. Risks for either VBAC or ERCD are listed as maternal hemorrhage (listed as
blood transfusion; respectively, 0.7-1.7%, 1-1.4%), infection (listed as endometritis;
respectively, 2.9%, 1.5-2.1%), operative injury (0.4%, 0.42-.6%), thromboembolism (not
listed), hysterectomy (0.2-0.5%, 0-0.4%), and maternal death (0.02%, 0.02-0.04%).
Another risk ACOG included was maternal morbidity, which is greater when TOL fails
and a rescue repeat cesarean becomes necessary. Therefore, it is safer for a woman with a
high probability of achieving a VBAC to attempt a TOL (ACOG, 2010). Included also
are tables to help assess this probability. Suggestions about counseling the woman from
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the beginning of maternity care in her second pregnancy are included with the ultimate
goal of the woman and her physician making the decision.
Lydon-Rochelle et al. (2010) reviewed information about short-term maternal
outcomes from 18 observational studies, which reported differences between outcomes of
VBAC and ERCD. The authors reported factors that might influence these outcome
differences and then compared successful VBACs and unsuccessful VBACs, identifying
knowledge gaps to assist in the management of dilemmas in childbirth after a cesarean.
Their event rates were similar to the ACOG (2010) practice bulletin which lists risks for
TOL and ERCD respectively, as follows: hysterectomy (0.1-0.3%, 0.1-0.5%),
thromboembolic event (0-0.6%, 0.1-0.5%), endometritis (1.0-8.2%, 1.2-8.8%), uterine
rupture (0.3-0.9%,0.0-0.2%), and maternal death (0.001-0.01%,0.005-0.04%). LydonRochelle et al. suggested that the frequency of these short-term maternal outcomes was
comparable to other common medical procedures, thereby dispelling the major
perception among clinicians, health-care payers, and women that an attempt for a VBAC
was very risky. Lydon-Rochelle’s team identified a lack of a randomized, controlled,
multicenter trial comparing TOL and ERCD to evaluate adverse outcomes for mother and
baby. They suggested that such a study be done.
Landon et al. (2004) performed a prospective four-year observational study from
19 medical centers across the United States. With a large cohort (N = 33,699), they
compared VBAC and ERCD and outcomes for mother and baby. This study group’s goal
was to provide information that was relevant for counseling a woman about her choices
in childbirth after a cesarean. They found symptomatic uterine rupture to occur in
women with TOL (0.7%). Hypoxic-ischemic encephalopathy occurred only in infants
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whose mothers had a TOL with the majority happening following a uterine rupture
(Landon et al., 2004).
Using the same goal, to provide the clinician information for counseling a woman
for childbirth after a cesarean, Cheng et al. (2011) built on the systematic evidence-based
review performed by Guise et al. (2010) and added information clinicians and patients
might need to make a choice between ERCD and TOL. They found that, in the United
States, among the women who had a TOL, 74% had a VBAC. This group also predicted
the probability of success for TOL, taking into account favorable and unfavorable factors,
which included indication for prior cesarean as favorable and increase in maternal age,
body mass index, preexisting maternal medical disease, and short interdelivery interval as
unfavorable. Cheng et al. (2011) reported higher risk of maternal mortality in ERCD,
13.4 per 100,000 (95% CI 4.3-41.6 per 100,000 ERCD) compared to 3.8 per 100,000 in
VBAC (95% CI 0.9-15.5 per 100,000 VBAC). Uterine rupture had an overall incidence
for both ERCD and TOL of 0.30% (95% CI 0.23%-0.40%); with 96% of the ruptures
occurring in the TOL group (Cheng et al., 2011). No statistically significant differences
were found in rates of hysterectomy, hemorrhage, infection or surgical injury between
ERCD and TOL.
Cahill et al. (2006) conducted a retrospective cohort study with 17 sites including
13,238 women who had prior cesarean deliveries to determine the safety of VBAC
compared to ERCD for their next birth. The primary outcomes identified for VBAC and
ERCD groups were as follows: uterine rupture for VBAC and ERCD respectively
(1.94%, 1.07%), bladder injury (0.51%, 0.44%), fever (11.21%, 12.11%), and need for
transfusion (0.87%, 1.08%). This study population considered women with prior vaginal
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deliveries and a prior cesarean as well as women without prior cesarean deliveries and
vaginal deliveries. They concluded that a woman with prior vaginal and cesarean
deliveries was the best candidate for a successful VBAC.
In a study of 1,408 deliveries performed at their facility, Loebel, Zelop, Egan, and
Wax (2004) included the same groups as above, VBAC and ERCD, but also included the
unsuccessful TOL women that had a rescue repeat cesarean. The outcome measures they
tracked were comparable for ERCD and VBAC: transfusion (0.9%, 0.6%), infection
(1.9%, 2.3%), uterine rupture (none in either group), and operative injury (0%, 0.4%),
respectively. Their population was from a large community hospital affiliated with a
university with no maternal deaths in the study time frame. A failed TOL reported risks
of adverse outcomes as transfusions (2.8%), infections (5.1%), uterine rupture (2.2%),
and operative injury (2.2%). The study concluded that outcomes were much worse for a
mother with a failed TOL.
From a prospective registry including 19 sites from 1999 to 2002, Mercer et al.
(2008) selected 13,532 women with one or more prior low transverse cesarean deliveries
(most common type of cesarean surgery) who wanted to attempt a VBAC in their current
pregnancy. Their goal was to estimate success rates and risks for a VBAC after one or
more previous cesareans. Among the women meeting their criteria, they found success of
VBAC increased after each VBAC and the risk of uterine rupture decreased with each
successful VBAC. The risk of maternal outcomes measured were similar in both groups,
including uterine rupture (first VBAC 0.87% and second 0.45%), hysterectomy (first
VBAC 0.23% and second 0.17%), surgical complications (first VBAC 0.45% and second
0.17%), thromboembolism (first VBAC 0.09% and second 0%), endometritis (first
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VBAC 3.68% and second 1.17%), and maternal death (first VBAC 0.02%, and second
0%). Regarding VBAC attempts, they concluded that 73% of women attempting VBAC
will succeed and 0.7% will have a uterine rupture.
Cahill et al. (2006), Cheng et al. (2011), Landon et al. (2004), Loebel et al.
(2004), and Lydon-Rochelle et al. (2010) determined the safety of VBAC when
compared with ERCD form their various research methods considering possible
complications. Mercer (2008) concluded his research dispelled the common perception
that a successful VBAC has as many complications as an ERCD. With the safety of a
TOL resulting in a successful VBAC seemingly established, where does a woman go to
have her TOL?
Access to TOL. In 2010, ACOG (2010) reviewed its previous statement that a
provider needs to be “immediately” available while a woman is attempting a TOL. They
upheld the statement that a facility that is providing care to a woman with a TOL must
have emergency surgery available. If this service is not available, ACOG (2010) suggests
the woman and her physician meet with the facility’s staff prior to her labor to discuss
hospital resources. If the facility is concordant with the ACOG recommendation, she
should proceed. If not, other options should be discussed to meet these recommendations.
As previously mentioned, in 2007, Roberts et al. (2007) found three out of every
10 hospitals (68 of 229 or 29.7%) that at one time allowed vaginal births after cesarean
had discontinued this practice. Furthermore, Cheng et al. (2011) reported one-half of all
hospitals in the United States have the capability for TOL and “immediate” availability of
emergency care. Therefore, offering women that are good candidates a choice between a
TOL and ERCD is not always possible.
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Fear of liability. The last controversy to consider is the physician’s fear of
liability. Health-care payers, women, and providers perceive that this fear is a major
driver of the increase in the cesarean delivery rate (Minkoff, 2012). Minkoff contends
that concerns about “defensive medicine” and cesarean deliveries are reflected in
physicians’ reports in a survey that they have practiced defensive medicine in the past
year.
Physicians also noted they are aware that this practice of defensive medicine, that
is, ordering more tests and doing more procedures than might be necessary, can increase
health-care costs. Baicker et al. (2007) reported that this increase in spending did not
affect patient mortality. Studdert et al. (2005) surveyed six high-liability medical
specialties in Pennsylvania (N = 824) to assess how often physicians changed their
clinical decision-making because of the threat of malpractice liability. On the
questionnaire, obstetricians acknowledged that their defensive behaviors were mostly
with high-risk patients (7%) and performing cesarean sections (6%).
Based on the realities of litigation, most obstetricians have been sued once, the
first time being in their residency (Minkoff, 2012). VBAC is the seventh most common
reason for a medical lawsuit, one ahead of operative vaginal delivery. Other reasons
listed in obstetrical litigation involve, in some manner, allegations about the failure to
perform a cesarean in a more timely fashion. Minkoff (2012) ends his review with doubt
that meaningful tort reform would help this practice of defensive medicine and asks his
fellow professionals to follow their professional obligation to serve the patient’s interests
first.
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Cost
In 2007 the Institutes for Healthcare Improvement (IHI) formulated a plan to
improve the U.S. health-care system. This plan has proposed “a simultaneous pursuit of
three aims (triple-aim): improving the experience of care, improving the health of
populations, and reducing the per capita cost of health care” (Berwick, Nolan, &
Whittington, 2008, p. 759). An example of using these aims simultaneously would be
using shared decision-making to improve the experience of care, which could decrease
the cost to the health-care system by decreasing the number of ERCDs while improving
the outcomes for mothers and babies. Berwick et al. (2008) said that the first step to
approach controlling cost is to put in place a system to measure and make transparent the
per capita cost for a defined population.
IHI (2009) included roles for integration of these components in the triple-aim
concept. As this is a systems approach, they defined macro and micro integrators. A
macro integrator is defined as an entity that can be a single organization that has the
ability to gather resources from numerous organizations to arrange an effective system to
support a defined population (IHI, 2009). Such a system could take the form of the
establishment of standards for using shared decision-making and making the cost of
procedures transparent to women. The micro integrator is defined as a single person or
team that improves the experience of care for a stated population. An example would be
the maternity care team.
In an economic analysis, cost is defined as the input measure to which the
consequences or output are compared (Drummond, Sculpher, Torrance, O’Brien, &
Stoddart, 2005). Rascati (2009) refers to costs as “resources used in the production of
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goods and services” (p. 237). The perspective of an economic analysis specifies which
costs to use from a certain point of view.
Hospital costs can be calculated as an estimate of resources used, as opposed to
charges, which are the bill a hospital sends to a health-care payer or patient for a case or
hospitalization. Charges do not necessarily reflect the actual cost of a hospitalization. The
AHRQ’s Healthcare Cost and Utilization Project (HCUP, 2012) converts total charges for
a case or hospitalization to costs using a cost-to-charge ratio, which is based on hospital
accounting reports from the Centers for Medicare and Medicaid Services (HCUP, 2012).
Hospital costs are most often less than charges and represent the true cost used in the
hospital’s production of the goods and service. Charges typically represent upcharges, or
embedded profits, for services provided. Also, facilities can be reimbursed a different
amount than cost-to-charge ratios due to a contracted arrangement for a certain amount
between the facility and health-care payer.
An economic analysis has two types of costs: variable and fixed. Direct and
indirect costs are considered variable costs because these costs might change due to the
intervention being considered. Rascati (2009) defines direct medical costs as those used
to directly provide a treatment. Indirect medical costs include a patient’s loss of
productivity due to an illness or medical intervention. Fixed costs, those costs that are
held at a constant level, which not part of the level of production and the time frame of
the analysis, are typically omitted in a cost-effectiveness analysis (Gold et al., 1996).
To estimate the cost of VBAC, ERCD and TOL, Grobman et al. (2000) used only
direct medical costs found in the published medical literature. When a value (direct cost)
was unavailable, the cost-to-charge ratio was calculated or expert opinion was sought. In
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the standard fashion, costs calculated and reported prior to 1999 were adjusted to 1999
dollars using the medical care component of the consumer price index, and future costs
were discounted at a rate of 3%. Direct medical costs were derived retrospectively from
reimbursement and medical records claims data. Direct medical costs reported were
VBAC $3,578, ERCD $5,511, and failed TOL $6,889 (Grobman et al, 2000).
Macario et al. (2004) used an alternative approach to estimating costs, which
attempted to use more accurate cost data. With this approach, called bottom-up or microcosting, it can be difficult to separate all the fixed costs from the variable components.
For instance, different labor and delivery units might have different variable costs
depending on how their staff is paid: hourly or salary. When compared to other similar
calculations done by another hospital in the same city, estimates were deemed consistent.
Costs for an ERCD were about $7,700, for a failed TOL about $9,800 and for an
uncomplicated vaginal delivery about $6,000. With any complication to mother or baby,
the total cost increased by about $6,000.
Another approach to considering cost is to use the societal perspective. Costs
from this perspective encompass “all costs and health effects regardless of who incurs the
costs and who obtains the effects” (Gold et al., p. 408). Using the societal perspective,
Chung et al. (2000) established baseline cost for uncomplicated VBAC as $4,950, ERCD
as $7,244, and failed TOL as $8,414. They also formulated incremental costs for
complications to be added to baseline costs.
Using actual hospital costs obtained from their hospital’s clinical resource
department, DiMaio et al. (2002) included direct and indirect medical costs, and fixed
costs. Their hospital’s procedural coding system adds labor, supply, and equipment for
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each revenue code. Incremental costs for complications were calculated based on mean
number of added hospital days. Reported costs without complications were ERCD
$4,155+/-661 and VBAC $3,675+/-936.
Using actual costs, Clark et al. (2000) derived estimated cost from diagnosisrelated group (DRG) data. These data were from 1996, covering 22 hospitals in the
western United States, totaling 26,000 births. DRG costs were VBAC $1,480 plus
anesthesia cost $674, ERCD $2,510 plus anesthesia $532, and failed TOL $2,735 plus
anesthesia $940.
Not only do the calculated costs vary in these studies, so do the methods of
calculating what their costs entailed. Clark et al. (2000), using 1996 cost data, quoted the
cost of ERCD at $2,510. Grobman et al. (2000) and Chung et al. (2000) used cost data for
cesarean as $5,511 and $7,244, respectively. DiMaio et al. (2002) cited ERCD costs at
$4,155. Macario et al. (2004) estimated costs for ERCD at $7,700. HCUPnet (2010),
using cost-to-charge ratio, quoted $4,749 as the cost for repeat cesarean delivery. Also,
because the costs are all estimates, some from a specific hospital and some from larger
data sets, and the perspectives vary, these numbers are hard to compare. Nonetheless,
each study found a TOL resulting in a successful VBAC as the most cost-effective.
Payment Reform
In 2009, United States health-care spending represented 17.6 % of the United
States Gross Domestic Product (GDP, Grubmuller, 2009). By 2017, the share of the GDP
devoted to healthcare is predicted to reach 19.5 % (Grubmuller, 2009). Government
economists predict that between 2007 and 2017, U.S. health-care spending will nearly
double (Grubmuller, 2009). These numbers reflect a looming financial crisis. Fixing the
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U.S. health-care system will require a multifaceted approach. One possible reform that
might affect a change in this growing industry is how we pay for care (Miller, 2009).
Under the current fee-for-service payment system, physicians, hospitals, and other
health-care providers are paid primarily based on how many services they deliver. They
are paid for volume (Miller, 2012). However, the literature on payment reform is
inconclusive on whether physicians may or may not be influenced by the amount of
payment for their services, traditionally fee-for-service (Miller, 2012; Schneider, Hussey,
& Schnyer, 2011). Additionally, each physician, laboratory, hospital, and other healthcare provider involved in the patient’s care is paid separately. This can result in paying
for duplicate services and tests for the same patient. In this fee-for-service system there is
no incentive to providers to coordinate care (Miller, 2012). Low, if any, payment is given
for preventive care or care coordination services. Because of these problems, significant
changes are needed in the way providers are paid for health care to aid in reducing costs
(Miller, 2012).
Fixing how care is paid for with alternate payment plans entails many issues. For
example, one strategy of payment reform is not to debate why a procedure, such as a
cesarean delivery, is performed. But debating why low-risk cesarean deliveries are
performed might affect change (Druzin & Sayed, 2006). Additionally, reviewing the
current medical literature on present patterns of reimbursement and possible provider
incentive programs could aid in the system reforms necessary for a change (Schneider et
al., 2011).
Purchasers and insurers have suggested changes in payment plans for health-care
services, and reforms for maternity care payments have been developed as alternate
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payment models away from fee-for-service. There is some evidence to support the use of
one of these alternate payment plans: bundled payments (Catalyst for Payment Reform,
2012).
In the obstetrical community, in conversations with patients discussing the risks
and benefits of ERCD or between colleagues discussing their own beliefs, considerable
controversy exists. Druzin and El-Sayed (2006) addressed one of the major aspects of this
controversy: maternal request for elective cesarean deliveries. In Brazil, the country with
the highest cesarean rate in the world (close to 60%), socioeconomic class determines
whether or not a woman receives a cesarean section by maternal request. Women in the
higher classes ask and receive elective cesarean deliveries, whereas the lower class
women are not given this option. Grant (2009) arrived at the striking conclusion that
some U.S. physicians perform ERCD because they receive higher reimbursement for that
procedure than for a TOL after cesarean.
Keeler and Brodie (1993) found a sizable difference in cost (including hospital
cost and physician reimbursement) between an ERCD and a VBAC. They suggested that
for a vaginal delivery, payment reform should start with a split in savings between “the
mothers for their labor pains, physicians for their time and effort, and hospitals for their
backup capacity that allows them to persist with difficult vaginal deliveries” (Keeler &
Brodie 1993, p. 393). They also recounted that physician reimbursement rates for
uncomplicated cesarean deliveries and vaginal deliveries equalized in 1993, after
physicians were surveyed by Blue Cross Blue Shield on their costs (fees) for each
procedure. Blue Cross changed its reimbursement practices and a few other commercial
insurers followed suit. Consequently, in certain parts of the U.S., uncomplicated cesarean
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deliveries and vaginal deliveries were then reimbursed the same amount (Keeler &
Brodie, 1993).
Gruber, Kim, and Mayzlin (1999) compared cesarean delivery rates between
Medicare and Medicaid recipients and private insurers, assessing causality for differing
cesarean delivery rates and reimbursement rates. They found a positive relationship
between cesarean delivery rates and fee differentials. This fee differential was large
enough to explain why Medicaid recipients had more cesarean deliveries than privately
insured women did. On the other hand, Keeler and Fok (1996) studied physician fee
changes instituted in California with the goal of decreasing cesarean rates, concluding
that equalizing physician fees (payment was the same for elective repeat cesarean
deliveries and vaginal births after cesarean) had little effect on cesarean rates.
Keeler and Brodie (1993) determined that economic incentives rarely affect
physicians’ medical decision -making. They examined other factors that might influence
physicians’ behavior and reduce cesarean delivery rates, and cited competition with
midwives and birth centers (where there is only a 7% cesarean rate) as a possible factor.
Payment reform efforts from purchasers and insurers currently focus on
approaches that include incentives to improve quality and reduce the use of costly
services (Schneider et al., 2011). In 2010, the Affordable Care Act (ACA, 2010)
incorporated some such payment reform measures. Cost containment efforts under the
ACA are centered on reversing incentives built into fee-for-service payments to increase
services by shifting some of the financial risk to providers. The goal of this strategy is to
prompt consideration of the cost for the provider’s decision, provide incentives for
efficiency, and align payment incentives with quality goals. In turn, providers might
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increase and maintain appropriate and necessary care, create care responsive to patients’
needs, and promote safer care. Schneider et al. (2011) suggested that new payment
schedules are not enough to comprehensively reduce costs. They proposed new payment
reform models, which include the following:


Global payments – These consist of a single monthly payment per
member per month for all services delivered for this patient from a mix of
providers. Payments may be adjusted depending on measured provider
performance and patient’s risk.



Accountable Care Organization (ACO) shared programs – This refers to
groups of providers (ACOs) that voluntarily assume responsibility for
delivery and services of care for a population of patients. Shared savings
come when this group meets quality and cost performance measures.



Medical homes – A group or single physician may receive additional
payments if medical home criteria are met. Payment may be determined
through a quality and cost performance mechanism.



Bundled payments – A single bundled payment is made for services
provided during an “episode” of care related to a medical condition or
procedure. Payment might be to multiple providers in multiple settings.



Hospital physician gainsharing – This is payment that allows a hospital to
pay physicians. It represents shared savings resulting from the physician
and hospital providing collaborative services that improve quality and
efficiency.

41


Payments for coordination – Payment made to providers that supply care
coordination services to integrate care between providers.



Hospital P4P (Pay for Performance) – Payments to the hospitals based on
whether they meet or miss performance benchmarks.



Payment adjustments for readmissions – Hospital payments are adjusted
based on potentially avoidable readmissions.



Payment adjustments for potential hospital acquired conditions –
Hospitals are penalized for high rates of hospital-acquired conditions or
are not reimbursed.



Physician P4P – Payments to physicians are based on whether they make
or miss performance benchmarks.



Payments for shared decision-making – Payment are made for
establishing shared decision-making services (Schneider et al., 2011).

Two of these payment reform models are especially relevant to maternity care:
bundling payments and shared decision-making. Payments for maternity care are most
often bundled but are separated into outpatient services and inpatient care. Shared
decision-making can be offered but is not presently standard in payment models.
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Bundled Payments. Conceptually, bundled payments decrease health care spending
while improving quality of care by generating financial incentives for providers to
exclude unnecessary services that are clinically ineffective or duplicative (Schoen,
Guterman, Zessa, & Abrams, 2013). This could also possibly encourage coordination of
care by holding multiple providers and hospitals accountable, through shared payments,
for cost of bundled care. Bundled payments could potentially work well for maternity
care (Hussey, Ridgely, & Rosenthal, 2011; Schoen et al., 2013). Although there is little
empirical evidence at present to support the use of bundled payments, there is an
experimental payment model being tested for bundling care that is managed and
implemented by Health Care Incentives Improvement Institute, a nonprofit organization
that also manages Bridges for Excellence (an organization that measures and provides
incentives to providers for quality work; Hussey et al., 2011). This model is called
PROMETHEUS, which is an acronym for Provider Payment Reform for Outcomes,
Margins, Evidence, Transparency, Hassle Reduction, Excellence, Understandability, and
Sustainability. The goal of the Health Care Incentives Improvement Institute is to
determine whether this model works in real-world conditions.
Key tools in the PROMETHEUS model are the use of evidence-informed case
rates, provider quality score cards, and potentially avoidable (incidents) scorecards. As a
comprehensive episode of care is established, the PROMETHEUS payment model
centers payment around all services related to that single illness. Costs for treatments are
calculated into the evidence-informed case rate. This case rate can be adjusted for
complexity of the patient’s individual condition. This bundled care includes, for example,
services such as hospital, laboratory, pharmacy, and radiologic testing services. The
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comprehensive quality scorecard encompasses metrics that track and evaluate care across
the entire span of treatment including provider performance measures in meeting clinical
practice guidelines for positive patient outcomes, avoidance of preventable
complications, and patient satisfaction. The PROMETHEUS payment model rewards
providers with an incentive program for improving care and reducing avoidable
complications.
Many pilot programs under the PROMETHEUS model have been developed
using the episodes of care for heart attacks, hip and knee replacements, diabetes, asthma,
congestive heart failure and hypertension. Taken together, these conditions represent a
potential impact on 30% of the adult insured population (PROMETHEUS Payment,
2009).
Hussey et al. (2011) discovered conceptual challenges when implementing this
model, including defining bundles, defining payment methods, implementing quality
measurement, determining accountability, engaging providers, and establishing delivery
designs. In spite of these challenges, all three pilot sites testing this payment model have
begun to at least implement quality measurements and have found them to improve care
and add care coordination to their teams.
Catalyst for Payment Reform (CPR), a nonprofit organization working for
coordinated action among the largest purchasers of healthcare (CPR, 2010), contends the
present bundle payment system for maternity service needs to be reformed. Currently,
outpatient health-care providers for maternity care have a bundled payment system that
encompasses the health-care provider’s delivery fees. The hospital then uses the fee-forservice payment mechanism for hospitalization for the birth portion of pregnancy. The
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hospital is then paid a case rate with the ability to add additional payments for
complications. This fee-for-service system is based on the type of birth a woman has
knowing a cesarean delivery is reimbursed at a 40% higher rate than a vaginal delivery
(Cunningham et al., 2010). CPR suggests a blended facility payment for delivery,
creating a single rate whether the birth is vaginal or cesarean. This rate would assume an
overall cesarean rate of 32% (or could be calculated for a lower rate) and would combine
cesarean costs and vaginal delivery costs. Their example was from 2005 data; with a
vaginal delivery cost of $7,773 and a cesarean delivery cost of $10,958, the blended rate
would be $8,792. This would remove the financial incentives for cesarean deliveries for
both the hospital and provider without the involvement of the health-care payer.
CPR (2010) reported that the Minnesota Department of Human Services has tried
this method with Medicaid payments in 2010. The blended rate was set based on the
assumption that there would be 5% fewer cesarean that vaginal deliveries. Minnesota
projected an estimated facility savings at $2.25 million annually (based on 26,195
Medicaid-paid births).
CPR (2010) also recommended advancing efforts to combine bundled maternity
care payments to encompass comprehensive payments for the women and their
newborns. Three approaches were recommended, each with different incentives:


Bundle professional (obstetrician or midwife) fee and hospital birth
payment for labor and delivery into one payment (Main et al., 2011). This
would encourage hospitals and providers to coordinate efforts to reduce
cesarean rates and improve quality of maternity care. It would also give
the hospital a financial lever to use with the providers, helping reduce
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unnecessary interventions. The system gets the payment then pays the
professional.


Bundle the hospital delivery payment for both mother and baby into one
payment (Main et al., 2011). This bundle would add the baby’s immediate
cost of care to the mother’s expenses. Any neonatal intensive care unit
expense for a term infant would be included in this bundle. Additional
payments would be made for outliers such as prematurity or known
congenital anomalies.



Establish a comprehensive bundled payment for maternity care episode.
One single payment, risk adjusted, would be made for pregnancy,
laboratory tests, ultrasounds, and actual delivery including anesthesia. The
provider would be paid per pregnancy at the same rate regardless of
resources used. One consistent single payment is meant to lead to lower
cesarean rates, lower complication rates, and higher profit margins.

Replacing current maternity care payment systems with systems that promote
affordability, advance clinical quality, foster prevention, coordinate care and safety, and
promote better patient outcomes would have positive implications for mothers and
babies. CPR (2011) contends these reforms should be balanced with realistic goals for
implementation and should consider a timeline that takes into account the need to change
a complex system reflecting geography, delivery system organizations, type of payee, and
patient characteristics. Payment reform mechanisms must ensure that the patients receive
the right care by the right provider at the right time, incorporating the values and
preferences of the patient (Berwick et al., 2008).
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Challenges in implementation of bundled payment involve two competing
systems function at the same instance, fee-for-service and bundle payments. Future
challenges are cited as:


Aligning physician practices with a shift from volume of service to value
and quality outcomes (Delisle. 2013).



Sharing financial risk management between health-care payers and
providers (Snoop, Huckfeldt, Escarce, Grabowski, & Newhouse, 2011).



Coordinating integrated delivery-of-care systems between acute and postacute settings.



Managing financially bundled payments claims processes (Weeks, Rauh,
Wadsworth, & Weinstein, 2013).



Coordinating information to ensure effective communication that
facilitates care coordination, exchange of information among providers,
and increases access to and transparency of data (Delisle, 2013).



Standardizing clinical processes by use of evidence-based practice to
ensure a reduction in cost and improvement in consistencies of outcomes
(Weeks et al., 2013).

Changes in reimbursement such as bundled payments will cause a systematic
transformation in delivery, healthcare, health-care provider operations, and consumer
perspectives (Delisle, 2013). Implementation challenges in this paradigm shift from
volume to value will be a complex system. This method of payment reform is meant to
provide value and appropriate levels of use and not punish efficiencies (Weeks et al.,
2013).
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Shared Decision-Making. The ACA (2010) established the Centers for Medicare and
Medicaid Innovation and authorized one billion dollars to test payment reform models
and delivery of care innovations. One of the delivery of care innovations is shared
decision-making and the use of decision aids. The Informed Medical Decisions
Foundation and Childbirth Connection, two not-for-profit organizations, have formed a
collaborative effort to integrate shared decision-making into maternity care by developing
decision aids for women with low literacy skills (Informed Medical Decision Foundation,
2011). Patients and providers at ten sites across the country will test these aids at ten sites
across the country. Decisional aids in the form of videos, websites or pamphlets can add
value to a preference-sensitive decision, even though these are thought to be nonessential
elements for informing patients.
Stacy et al. (2011) reported that decisional aids increase knowledge, lower
decisional conflict, and reduce the number of people who choose major elective invasive
surgery. As an extensive Cochrane review, Stacy et al. (2011) noted no adverse effects on
health outcomes or patient satisfaction when using shared decision-making and decisional
aids. They also indicated that cost of implementation has been only slightly studied,
which was thought to be a barrier for some sites to implement this practice.
Implementation and evaluation of these practices will provide important data for
improving cost containment and quality. Hussey et al. (2011) warned changing to this
new system will take time and considerable effort. How payers and providers share the
risk of episodes of care seem to be the center of the debate (Hussey et al., 2011).
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In sum, knowing the cost-effectiveness of ERCD and TOL could add useful
information to this policy debate about maternity care payment reform. In establishing
the blended facility rate for deliveries, knowing which mode of delivery is more costeffective could assist in the use of rate-setting to attempt to adjust cesarean rates. Healthcare providers can consider shared decision-making as a mechanism to increase TOL
rates. They might have an incentive to do so if health-care payers implement a bundled
payment system or similar reforms. Health-care payers, in turn, could support shared
decision-making knowing its potential to decrease decisional conflict. For maternity care,
shared decision-making could promote the decision to avoid elective surgery by 25%
(Stacey et al., 2011).
Framework for Economic Analysis in Medicine
This section of the literature review presents a framework for performing
economic evaluations or analyses in medicine. Economic evaluations are essentially
concerned with choices, utilization of scarce resources, and costs and consequences of
human activities (Drummond, et al., 2005; Siegal, 2005). Consequently, two basic
characteristics underlie an economic analysis (Drummond et al., 2005). First, economic
evaluations assess the costs (resources used) and consequences of each competing
therapy. Second, economic evaluations are concerned with the choices made between
alternate therapies, taking into account the scarcity of resources used by those therapies.
Therefore, the basic purpose of an economic evaluation is to identify and make explicit
one set of criteria, which may be useful in choosing among different uses of scarce
resources.

49
Drummond et al. (2005) specify that the basic responsibility of any economic
evaluation is to identify, measure, value, and compare costs and consequences of the
alternatives being considered. As a characterization of all economic evaluations, two
components must be included: (a) a comparison of two or more alternatives and (b) an
examination of both costs (inputs) and consequences (outputs) of the alternatives.
To conduct an economic evaluation, three essential components are required
(Gray et al., 2011). The first is the perspective from which to evaluate the various costs
and benefits. The second is a formulation of costs to be included in the evaluation (direct,
indirect, and intangible). The third required component is a formulation of the economic
methodology for the given activity or health question under consideration. These
methodologies include cost-minimization, cost-effectiveness, cost-benefit, and costutility analysis.
Perspective in Economic Analyses. The perspective is the viewpoint from which the
study or analysis is conducted. It may assume the viewpoint of a single provider or
facility, health-care payer, health-care system, or society at large (Gold et al., 1996). It is
important to state explicitly the perspective of an economic evaluation, since the
perspective determines whose costs are relevant to the purpose of the study (Rascati,
2009).
Conventional economic theory suggests the societal perspective is the most
comprehensive approach (Gold et al., 1996; Rascati, 2009). Societal costs include cost
to the insurance company, cost to the patient, other sector costs, and indirect costs
because of loss of productivity of the patient and associated caregivers. It is difficult to
estimate all these costs accurately. However, in many cases the research question of
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interest more simply concerns differences in direct medical costs between two
alternatives. The most common perspectives used in pharmacoeconomics studies are
those of the institution, the provider or the payer because these may be more practical in
answering the query in hand than using the societal perspective (Rascati, 2009).
Costs in Economic Analyses. Direct costs in a medical intervention include the value of
all goods, and services that are used in the intervention. Direct costs consist of all types
of resources used in the direct production or provision of the medical intervention,
usually measured in monetary terms, and can have both medical and nonmedical
components. Direct medical costs are the most relevant costs to measure because they
include costs of tests, drugs, supplies, health-care personnel and medical facilities
(Rascati, 2009). Examples of direct nonmedical costs are family expenses for
transportation and lodging for family during the treatment.
Direct costs are those costs needed to direct and operate a program. They can be
divided into variable costs (supplies, hospital costs) and fixed or overhead costs (such as
rent, heat or capital costs). Direct costs are usually calculated by adding direct medical
and nonmedical costs for the intervention in question and the alternative therapy.
Indirect costs, also referred to as productivity costs, are the costs associated with
loss of or inability to work (temporary or permanent) or engage in leisure activities due to
a complication from the intervention (Gold et al., 1996). Haddix, Teutsch, and Corso
(2003) included opportunity costs in this concept. Opportunity costs are what a member
of society gives up for now and in the future to have a certain intervention. Opportunity
costs contain all monetary and nonmonetary costs of the treatment regardless of who
bears the cost: the provider, institution, or consumer. If the consumer is unable to work
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as the result of a treatment or test, society loses the benefit of that person’s contribution
in the work force, or that person’s healthy time is forfeited. This cost value is most often
only included in an economic analysis performed from the societal perspective (Haddix et
al., 2003).
Intangible costs include the cost of pain and suffering, or anxiety and fatigue that
happens due to the intervention or an illness. It is very difficult to place a monetary value
or measurement on this type of cost. Rascati (2009) incorporated intangible costs using
the willingness-to-pay technique in a cost-utility analysis. The willingness-to-pay method
estimates the cost of an injury or disease by calculating what society would be willing to
pay to avoid or reduce the likelihood of that injury or disease.
Methodology
Economists generally refer to four methods of economic analyses: costminimization, cost-effectiveness, cost-benefit, and cost-utilization. Cost-minimization
analysis is the simplest and costs the least to perform. It measures and compares the
input costs and assumes the consequences or outcomes are the same. The goal is to find
the least expensive method of achieving the specified outcome. A disadvantage of this
method is that it has limited use because it is designed to compare two interventions or
alternatives with the same outcomes, which rarely happens in the real world (Rascati,
2009).
Cost-effectiveness analysis is the most commonly used method of economic
analysis. It measures costs in dollars and outcomes or effectiveness in natural health or
clinical units. The goal is to identify the most cost-effective strategy from a set of
alternate therapies or interventions that produce a common effect. An incremental cost-
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effectiveness ratio (ICER), defined as the net cost between alternatives divided by the net
effectiveness between alternatives, is a focus of cost-effectiveness analysis (Haddix et al.,
2003). One disadvantage of this method is that its comparability between costeffectiveness studies can be limited because each study may have a different outcome
measure.
Haddix et al. (2003) touted the cost-benefit analysis as the “gold” standard for
economic analysis. This is because cost and benefits are reported using common metrics
(usually dollars), which allows for results to be compared for a wide range of public
programs. A cost-benefit analysis compares the value of all resources consumed with the
value of the outcomes from the intervention. This analysis compares society’s total
willingness-to-pay for an outcome with the opportunity cost of the intervention or
program.
Cost-benefit analysis has several advantages over a cost-effectiveness analysis.
Cost-benefit analysis can be applied to single or multiple interventions or programs,
whereas a cost-effectiveness analysis is applied only to multiple interventions or
programs. Cost-benefit analysis can be used to compare programs with different
outcomes, whereas a cost-effectiveness analysis isolates the least costly approach for a
single outcome. A disadvantage of a cost-benefit analysis is that it calculates its outcomes
in dollars only. However, some outcomes of great interest to health researchers, such as
lives saved, can be difficult to assign an exact monetary value to (Haddix et al., 2003).
Cost-utility analysis, like other economic analysis, compares alternative program
outcomes. The difference is that the outcome measure is stated as number of life years
saved, with a quality-of-life adjustment, usually measured in QALYs. The question being
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investigated in a cost-utility analysis establishes when this is an appropriate evaluation to
use. The study question could include the following components: (a) quality of life is an
important outcome, (b) the program being evaluated affects both morbidity and mortality,
(c) the programs or interventions being compared have a wide range of different
outcomes, and/or (d) the comparator intervention has already be evaluated using a costutility analysis (Haddix et al., 2003).
Framework for Conducting a Cost-Effectiveness Analysis
A cost-effectiveness analysis can be used to describe and contrast the costs and
outcomes for two or more health interventions. Usually an intervention (one or more) is
compared to the standard of care or most-often-used intervention, using costs and
outcomes for the same condition. The research question for a cost-effectiveness study is
about an intervention and its impact on health-care costs and health outcomes. The costeffectiveness analysis itself analyzes a series of decisions that formulates the study
framework. In a cost-effectiveness analysis, the added costs and health outcomes
associated with the interventions are used to calculate the incremental cost-effectiveness
ratio in relation to the alternate course of events (Gold et al., 1996). This incremental
cost-effectiveness ratio can provide an estimate of the additional cost per unit of
effectiveness. When an intervention is both more effective and less costly to the
alternative, it is said to dominate (Gold et al., 1996). In this case of dominance, there is
no need to calculate a cost-effectiveness ratio because dominant strategies are always
cost-effective.
Next, aspects of the target population are identified. Aspects of the population
can have an impact on the cost-effectiveness calculations. Researchers often identify and
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establish the population on the basis of previous research in the peer-reviewed literature.
Depending on the analysis, the target population may be identified by age, gender, race,
socioeconomic status, clinical history, geographic location, risk-related behaviors,
physiological risk factors, or other descriptors. Cost-effectiveness analyses for specific
subgroups within a target population may also be performed if indicated by the research
question. This would be, for example, relevant when studying different care settings or
subgroups in terms of race or age.
Boundaries, or scope of study, also need to be set. Defining the scope of a study
can be understood as drawing a circle around it. In circumscribing a study, an attempt is
made to include all significant events and health outcomes of said intervention that would
be relevant for the stated population. The time horizon of a cost-effectiveness analysis, as
part of the scope of a study, should extend far enough into the future to include all major
health and economic outcomes (Rascati, 2009).
Decision Analysis
A decision analysis is a systematic quantitative approach to decision-making
under uncertainty (Goldie & Corso, 2003). Decision science aims to develop and apply
systematic and logical structures to decision-making. Its representative feature is a focus
on the outcomes of decisions, including descriptions of any uncertainty about those
outcomes that exists when decisions are made. Decision analysis applies a prescriptive
approach, which allows one to make effective decisions in a consistent manner. Decision
analysis is most useful when multiple alternatives exist and the most efficient selection is
unclear.
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Another application of decision analysis is to provide policy-makers with a guide
to health-care allocation issues (Gray, Clarke, Wolstenholme, & Wordsworth, 2011).
This application of decision modeling has evolved due to the limitations and barriers of
other frameworks. An advantage of decision analysis is that the modeling process offers
an opportunity to prospectively collect and analyze patient-specific data on resource use
and outcomes and to quantify the effects of an intervention on those outcomes.
Application of decision analysis involves four steps: structuring the problem,
estimating probabilities, valuing outcomes, and selecting the option with the highest
expected value (Gray et al., 2011; Drummond et al., 2005; Haddix et al., 2003).
Structuring the problem includes stating the major issues, defining the perspective and
developing a decision tree. The term decision-tree is used here because this list of options
resembles a tree and its branches.
Structure of the Decision Model
Models are used to structure a decision or problem. The schematic model serves
as a guide in concrete, well-defined steps, which outline the event pathways stemming
from the use of the intervention and linking the intervention to health outcomes. The
model reflects the analyst’s formulation of how the intervention is used and how it affects
the course of the condition of interest, its treatments, and the health outcomes of the
target population. This model includes all relevant effects of the intervention being
considered: the events induced by the intervention, and intended and unintended effects.
As the event pathway is built to represent health effects, health states, and events that
have impacted health, it also reveals the cascade of cost implications caused by the
intervention (Gold et al., 1996). The model as a decision tree is assembled from left to
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right, starting with the initial decision node and moving to the right toward final
outcomes (representing a temporal sequence of events) while estimating probabilities for
each event (on the tree) that is subject to chance. Estimates of probabilities may come
from the published literature, previous research, actual data, or expert opinion.
Valuing outcomes involves assigning a value to each outcome on the decision
tree. The option with the highest expected value is selected after processes known as
averaging-out and folding-back the decision tree. The calculation of expected value
involves taking the individual products of values from outcomes and respective
probabilities for outcomes and then summing these products. In cost-effectiveness and
cost-utility analyses, the processes called averaging-out and folding-back are performed
twice. These processes are used for the first time to determine the cost of the studied
intervention and for the second time to determine the effectiveness of the intervention.
The results of these calculations are combined into summary ratios. To test the robustness
of the expected utility or expected value calculations, a sensitivity analysis is performed.
Review of Economic Evaluation of Cost-Effectiveness Comparing ERCD and TOL
This section summarizes the published economic evaluations that have been
performed comparing ERCD and TOL. It demonstrates the scarcity of this type of costeffectiveness analysis and the gaps in the literature. The purpose of this review is not to
tackle decision-making practices in obstetrics, such as indicated versus emergency
cesarean deliveries due to medical complications or the reason the first cesarean delivery
was performed. Rather, it is to review the cost-effectiveness of ERCD versus TOL. The
literature reviewed focused on the population of women with uncomplicated term
pregnancies with normal babies and one previous cesarean delivery.
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In June, 2010 and repeated in August, 2012, a literature search was performed
using PubMed, EconLit, Web of Science, and Google Scholar online citation indexing
services. Similar findings were found from both searches. Search terms included
variations of elective cesarean section, cesarean delivery, cost-effective, and costeffectiveness. A total of 1,384 articles were found initially in both PubMed and Web of
Science, using only cesarean section. With the addition of cost-effective, the search was
narrowed to 24 articles. EconLit revealed 17 articles when the search terms cost-effective
and cesarean section were entered. After applying the exclusion criteria (stated below),
three articles from the medical literature were identified that addressed elective cesarean
delivery and cost effectiveness using a cost-effectiveness analysis. Next, a search using
reference lists from clinical bulletins from 2005 to 2012 addressing VBAC and ERCD
revealed two more published cost-effectiveness analyses. The three articles previously
identified by the search of citation indices were also listed in the reference lists for the
clinical bulletins. A total of five articles were identified.
The search was limited to articles published in the U.S. between 2000 and 2012
involving term pregnancies with no known complications and with a history of one
previous cesarean section. Articles written prior to 2000 or involving high-risk pregnancy
conditions, including breech delivery, preterm delivery, low birth weight, multiple
gestation, HIV, hepatitis C, gestational diabetes, or preeclampsia, were excluded. Articles
written prior to 2000 were excluded because ACOG changed its provider guidelines for
VBACs in 1999.
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Synthesis of Studies on Cost-Effectiveness
Randomized controlled trials comparing an ERCD and a TOL after cesarean
section are not performed because of the ethical concerns inherent in this controversial
subject, particularly if cutting health-care costs is the stated goal. Instead of randomized
controlled trials, Clark et al. (2000), Chung et al. (2001) and Macario, El-Sayed and
Druzin (2004) used hypothetical populations to perform their cost-effectiveness analyses
of TOL versus ERCD. All three groups concluded that a TOL, when a vaginal delivery
without complications was successfully achieved, was more cost-effective than an
ERCD. They also found that if the TOL resulted in a cesarean delivery, the cost would be
greater than with an ERCD or vaginal delivery by thousands of dollars because of a
longer hospital stay and noted complications.
Grobman, Peaceman, and Socol (2000) used a decision tree to analyze the
reproductive life of a hypothetical cohort of 100,000 women with a history of cesarean
deliveries and the cost-effectiveness of a second delivery, whether ERCD versus TOL.
Their analysis showed an increase in mortality, morbidity, and cost with ERCD. The
perspective used was that of a single health-care system. Outcome measures used were
maternal and neonatal morbidity and mortality, total cost to their health-care system, and
cost per major neonatal complication avoided. They reported that prevention of one
additional adverse neonatal outcome required 1,591 additional cesarean deliveries to be
performed.
DiMaio et al. (2002) used a retrospective cohort analysis to review 204 medical
records. By reviewing the records of all women who delivered at their hospital in 1999
and had a history of one previous cesarean delivery prior to admission, they found a TOL
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to be more cost-effective than an ERCD. The outcome measure used for this study was
mean cost of hospital care for mother-infant pairs. Interestingly, by using only their own
institution’s data they could account for all costs incurred, varied and fixed. Many studies
are lacking in this area, because fixed cost varies between institutions. DiMaio et al.
(2002) concluded that although a TOL that resulted in a cesarean delivery cost more in
their institution, it was not by a significant amount. This group found that the mean cost
of care was higher for the ERCD, considering mother alone and mother-infant pairs as
separate groupings, than a TOL.
Chung et al. (2001) used a computer-generated hypothetical model of a 30-yearold woman pregnant with her second baby after having had a cesarean with her first.
They used actual hospital cost and quality-adjusted-life years for the mother (QALY: a
measure of disease burden, including both the quality and quantity of life lived) as their
outcome measure. Costs associated with moderate morbidity of the infant or probability
of infant morbidity heavily impacted their results. Chung et al. (2000) found, using
ERCD as their base case, an incremental cost-effectiveness ratio would result of
$112,023 per QALY. This level exceeds the traditional willingness-to-pay for a QALY
($50,000) and, hence, a TOL was calculated as the preferred method of delivery. That is,
the reason that TOL was cost-effective was both that it was lower cost and that the ICER
between TOL and ERCD was greater than the willingness to pay.
Also using QALYs as their outcome measure, Macario et al. (2004) used a
computerized model for their population to perform a cost-effectiveness analysis
comparing ERCD and VBAC. This group used a health utility measure scaling life from
death (0) to perfect health (1). They also used the traditional threshold for a QALY at
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$50,000. From a societal perspective, they found that a VBAC has an opportunity cost
associated with an obstetrician needing to miss part of his or her life in order to be
immediately available for a woman attempting a VBAC. This study explicitly stated it
was a cost-effectiveness analysis, but reported its results in cost-benefit ratios. The
authors found that “if a priori chance of TOL after a cesarean success is at least 74%,
then the cost/benefit profile favors a TOL” (Macario et al., 2004, p. 383).
Lastly, Clark et al. (2000) undertook a cost-effectiveness analysis comparing
TOL and ERCD by using an algorithm of the clinical course of a hypothetical patient
with a previous cesarean delivery. Costs were derived from DRGs for a large not-forprofit health-care system. The perspective was presumed to be that of a large health-care
system. The effectiveness measure was perinatal morbidity. The study focused on total
medical costs for a trial of labor and intended to add information, using a shared decisionmaking model, to the risks and benefits conversation for women deciding between each
procedure. They found that an ERCD was associated with greater short-term perinatal
morbidity than a vaginal birth. Their findings indicated ERCD was more cost-effective to
the health-care system.
The proposed purpose of these five studies was similar. The population of interest
was also similar: women in their second pregnancies who had had a first pregnancy
resulting in a cesarean delivery. Three studies, Clark et al. (2000), Chung et al. (2001),
and Macario et al. (2004), used hypothetical populations and concluded that if a TOL
resulted in an uncomplicated vaginal delivery, TOL was more cost-effective. Grobman et
al. (2000), using a hypothetical cohort and a decision tree for their cost-effectiveness
analysis, found increases in mortality, morbidity, and cost with an ERCD compared to a
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TOL. DiMaio et al. (2002) performed a retrospective chart review and found a TOL to
be more cost-effective than an ERCD. Basically, although these studies used varying
perspectives on costs and measures of effectiveness, the resulting conclusions were
similar.
Summary
This chapter reviewed literature related to pregnancy and maternity care, modes
of delivery for the first pregnancy, options for the delivery of second pregnancy, and how
providers and patients might choose among options for the second pregnancy when the
first pregnancy resulted in a cesarean. This review was followed by an overview of the
literature related to how the choice is made for ERCD or TOL using shared decisionmaking. It focused on bioethical aspects of shared decision-making: the mother’s
autonomy, the provider’s beneficence, and differences among beneficence, autonomy,
and social justice.
Next, the chapter discussed issues related to access to a TOL. As some women
are now opting for a TOL, providers, researchers, and payers need to understand the
controversies surrounding it. Results of past economic analyses of complication rates
vary greatly from study to study. This variability enhances confusion about optimal
delivery options for women and their babies. Major challenges in this area include lack of
access to a TOL and providers’ fear of liability.
This chapter also reviewed the major aspects of cost used in the published
literature pertaining to cost-effectiveness analyses. It also discussed different methods to
evaluate costs for economic analyses. Among the many challenges to drawing

62
comparisons across cost-effectiveness studies is that each study may use a different
perspective for determining costs and different measure of effectiveness.
A review of payment reform as it relates to the health-care payer was also part of
this chapter. It includes findings from the Catalyst for Payment Reform, which
prescribed a few methods for payment system reform for maternity care. Other payment
reform options, such as bundled payments and accountable care organizations, were also
discussed.
A review of the literature on economic evaluation in medicine summarized the
types of economic analyses considered in this study. This review was followed by a
discussion of decision analysis and cost-effectiveness analysis. This chapter concluded
with a review of cost-effectiveness analysis, comparing ERCD and TOL.
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Chapter 3
Methods
This chapter addresses the research design and methods used in conducting the
study objectives and are divided into nine sections: (a) Human Subjects Review, (b)
Study variables, (c) Research Design, (d) Cost measures, (e) Effectiveness measures, (f)
Model Inputs, (g) Calculation of Cost-Effectiveness, (h) Sensitivity Analysis, and (i)
Summary.
Human Subjects Review
Although most academic departments require that researchers receive approval
from the institutional review board, certain types of studies are exempt from such review.
Studies that are exempt by the Human Research Review Committee (HRRC) at the
University of New Mexico (UNM) Health Science Center (HSC) include research
involving publicly available data. The estimates used in this study were publicly
available from the peer-reviewed literature and from the Healthcare Cost and Utilization
Project (HCUP) supported by Agency for Healthcare Research and Quality (AHRQ).
Accordingly, the HRRC at UNM HSC confirmed that this study did not require HRRC
approval.
Study Variables
Independent Variable
This study included one independent variable with two levels. The independent
variable was the mode of delivery chosen by a woman in her second pregnancy, who had
delivered by cesarean with her first birth. One level of the independent variable was an
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elective repeat cesarean delivery (ERCD) after 39 weeks gestation. The second level of
the independent variable was a trial of labor (TOL).
Dependent Variable
This study had two types of dependent variables: cost and effectiveness. Direct
medical costs, including normal delivery costs and medical complication costs related to
delivery, were calculated for both the mother and baby. Possible maternal complications
included hemorrhage, infection, thromboembolic event, operative injury, hysterectomy,
uterine rupture/dehiscence, and maternal death. Possible baby complications included
respiratory distresses, sepsis, hypoxic ischemic encephalopathy (HIE), and fetal death.
Effectiveness was measured by length of hospital stay for both the mother and the baby,
including a normal hospital stay related to the delivery and possible additional time spent
for possible medical complications.
Research Design
The overall purpose of this research was to determine the cost-effectiveness of
ERCD compared with TOL in low-risk women who had a cesarean delivery with their
first pregnancy and were in their second pregnancy. This analysis compares the costeffectiveness of ERCD versus TOL from the perspective of the health-care payer by
calculating incremental cost-effectiveness ratios for the alternatives ERCD versus TOL
when applied to cost and effectiveness related to the mothers and babies.
Decision Analysis Model
As a systematic, quantitative, and visual approach, a decision analysis can be used
for addressing and evaluating issues related to medical decisions. The decision analysis
model used in this study was an event pathway, built to represent health effects, health
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states, and events that have impacted the health of a given population. The event pathway
also reveals the cascade of cost implications caused by the intervention (Gold et al.,
1996). The starting point in a decision analysis model is the decision between two
alternatives. In this study, the decision considered was the choice the mother made
between an ERCD and a TOL.
Model Specifications
Developing a model for a decision analysis entails several components: creating a
decision tree, selecting the data source, developing the model probabilities, identifying
the outcomes (terminal nodes) of interest, and stating the model assumptions. The
following sections discuss each of these key components for developing a model for
decision analysis used in this study.
Development of decision trees. A simulated model was constructed using a
decision tree created with TreeAge Pro Healthcare (2012). The decision tree includes
two branches related to a woman’s decision between an ERCD (preformed at 39 weeks’
gestation) and a TOL after previous cesarean delivery (See Figure 1). This original
decision node represents the decision in question and is represented as a square in the
decision tree. The TOL branch was then divided again into two scenarios, vaginal birth
after cesarean (VBAC) or rescue cesarean delivery (RCD). The decision tree was then
extended from left to right, starting with the decision nodes. The events that follow are
clinical events and/or possible complications incurred as a result of the original decision,
ERCD or TOL. These are chance events and are represented by chance nodes or circles
in the decision tree. Events for each chance node are represented by lines (branches) that
extend from a node. The likelihood of an event is represented by the event probability.
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Events stemming from a chance node must be mutually exclusive, and probabilities of
each chance node must sum to exactly one.
The final outcomes from these chance pathways in the decision tree end in a
terminal nodes, represented by triangles in the decision tree. Each terminal node has
values assigned to it for both cost and effectiveness. For the mother, possible events and
complications resulting from an ERCD or a TOL were included as branches in the model
and labeled as follows: no complications, thromboembolic event, infection, operative
injury, hemorrhage, hysterectomy, uterine dehiscence/rupture, and maternal death.
Because these risks are related to mode of delivery, the maternal events and
complications and their probabilities were considered with each possible mode of
delivery: ERCD, VBAC or RCD (Figure 1).
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Figure 1. Maternal decision tree.
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A second tree was constructed to consider the clinical events, complications and
event probabilities incurred by the baby as a result of the mother’s decision between an
ERCD and a TOL (Figure 2). This decision tree has, broadly speaking, the same
appearance as the mother’s tree, and it depicts events and complications that the baby
incurred for each procedure. These events and complications are chance nodes from each
mode of delivery and are labeled as no complications, respiratory distress, sepsis, HIE,
and neonatal death.
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Figure 2. Baby decision tree
Perspective. This cost-effectiveness study analyzed costs from the perspective of
the health-care payer. Health-care payers for this study were self-pay, Medicaid,
Medicare, and private insurance. All cost components that went into the development of
this model were determined by estimates of cost-to-charge ratios for hospital care
reflected as direct medical costs to the health-care payer.
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Data source. The data source for costs in this study was the Agency for
Healthcare Research and Quality’s (AHRQ) Healthcare Cost and Utilization Project
(HCUP), (HCUPnet, 2012). A query was performed of the 2010 HCUPnet for cost data
from health-care payers, which included self-pay, Medicaid, Medicare, and private
insurance. AHRQ sponsors HCUP (2012), which is a “family of powerful health-care
databases, software tools, and products designed to advance health-care research as it
relates to health services, policy, and clinical research” (HCUP, 2012, p. 1). HCUP
(2012) is the largest collection of multiyear, all-payer, encounter-level data based on
inpatient, ambulatory and emergency department billing records including all listed
clinical diagnoses and procedures, discharge status, and patient demographics since 1988.
As a federal-state-industry partnership to compile and create a national information
resource, HCUP (2012) brings together data from many organizations: state data
organizations, such as hospital associations and state health departments; private data
organizations, such as the American Hospital Association; and the federal government.
Hospital costs included in HCUP (2012) are from community hospitals, defined as shortterm, nonfederal, general and other hospitals, excluding prisons and Indian Health
Service. The HCUP database includes obstetrics and gynecology encounters totaling
approximately 4 million birth records. HCUP (2012) data is derived from the State
Inpatient Databases (SID), State Ambulatory Surgery Databases (SASD), and State
Emergency Department Databases (SEDD) to derive three nationwide stratified sample
databases: the National Inpatient Sample (NIS), the Kids’ Inpatient Database (KID), and
the Nationwide Emergency Department Sample (NEDS).
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HCUPnet data. HCUPnet (2012) is a free, interactive, publicly available online
query system based on aggregated tables which AHRQ established from the NIS HCUP
data. As a stratified sample of hospitals, NIS is 20% of the SID, totaling 1,000 hospitals
and 8 million records. This sample is stratified by five characteristics: U.S. region,
urban/rural, teaching status of hospital, ownership/control of hospital, and bed size.
Researchers may query by diagnoses and procedures using the International
Classification of Diseases, 9th revision, Clinical Modification (ICD-9-CM) codes,
Diagnosis Related Groupings (DRG) codes, and Clinical Classification Software (CCS)
categories. HCUPnet (2012) CCS classifies data into clinically meaningful categories,
facilitating understanding of clinically grouped patterns. HCUPnet provides estimates on
selected outcome measures including number of patients discharged from the hospital,
length of hospital stay, total hospital charges, and total costs.
HCUPnet (2012) issues reports of descriptive statistics of specific diagnoses and
procedures by year and ICD-9-CM, DRG, and CCS codes. Cost and effectiveness
estimates for 2010 for the cost-effectiveness analyses in this study were taken from
queries of the HCUPnet data. Tables were created, across all payers and all U.S. regions
including 45 states. Median cost estimates were derived using cost-to-charges ratios and
effectiveness measures were taken from mean length of hospital stay for mother and
baby.
Estimates from the peer-reviewed literature. Probability estimates for the
maternal and baby events pathways in the decision analysis were obtained from peerreviewed literature (DeLuca, Boulvan, Irion, Berner, & Pfister, 2009; Go, Emeis, Guise,
& Schelonka, 2011; Hibbard, Ismail, Wang, Te, & Karrison, 2001; Hook, Kiwi, Amini,
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Fanaroff, & Hack, 1997; Kamath et al., 2009; Landon et al., 2004; Levine, Ghai, Barton
& Strom, 2001; Menacker et al., 2010; O’Shea, Klebanoff, & Signore, 2010; Patel &
Jain, 2010; Spong et al., 2007; Yee, Amin, & Wood, 2008).
Target population. The target population for this analysis was women in their
second pregnancy when the first pregnancy resulted in a cesarean delivery choosing
between an ERCD and a TOL. These women were low-risk, at-term, and singleton
pregnancies, with the fetal head as the presenting part.
Time Horizon. Gold et al. (1996) recommended that a time horizon adopted for
cost-effectiveness analysis should be long enough to capture all relevant effects of the
intervention being studied. The time horizon for this study was from time of hospital
admission of the mother for delivery until she and the baby were discharged from the
hospital. This encompassed the cost to the health-care payer for the mode of delivery and
possible events and complications incurred by both the mother and baby during their
length of stay. No discounting was necessary because direct medical costs were all from
the same year with no modification necessary for future estimates.
Model Assumptions
In specifying the structure of the decision analysis model, certain assumptions
were made. Maternal clinical events and complications for each decision were obtained
from the peer-reviewed medical literature based on a meta-analysis performed by Rossi
and Addario (2008), who documented these events as the most common complications.
Although some of these maternal complications are rare events, when they occur they are
a high expense in direct medical costs and may add to the length of hospital stay for the
mother and baby. Base case probabilities were established from the estimate of the event
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that was most likely to occur. Another assumption was that in the event of maternal
death the mother died at delivery. This assumption was important because a death later,
after delivery, would incur additional costs by the day, varying by the complication, and
may not always be directly attributable to the mode of delivery. Additionally, in the
event of fetal death, the model assumes fetal death also occurs at time of delivery. This
assumption was important because, as with the mother, additional costs would be
incurred which would vary according to the complication, and may not always be a
casualty of the mode of birth.
Cost measures
Given the perspective of this analysis (the health-care payer), only direct medical
costs were used in the cost-effectiveness analysis. These costs were as follows: (a) direct
medical costs incurred for hospitalization for ERCD and TOL for mother and baby, and
(b) direct medical costs related to events and complications from modes of delivery
(ERCD and TOL) for mother and baby. Clinical complication costs for both the mother
and baby were derived from the HCUPnet aggregated cost estimates using 2010 data.
HCUPnet cost data uses cost-to-charge ratios only for hospital costs, not including
physician fees or outpatient costs.
The use of aggregated cost data such as available from HCUPnet is supported by
Berwick et al. (2008) since the considerations of population-level measures is a
precondition to credibly pursuing the “triple aim.” Additionally, looking at care
utilization among pregnant women is consistent with Berk and Monheit (2001) strategy
of focusing cost containment strategies on conditions that affect large percentages of
populations. This focus allows for a concentration on health-care spending that reflects a

74
concern over equity and the efficiency with which resources are used. Therefore, the
value of using aggregate cost data from HCUPnet (2012) from the perspective of the
health-care payer (Medicaid, Medicare, self-pay and private insurance) accounts is that
aggregation averages out the uneven distribution of health-care expenditures among
different health-care payers by weighting high costs alongside low costs. Berk and
Monheit found that the top 5% of health-care expenditures among the privately insured
doubled what was spent by the uninsured. Using HCUPnet’s (2012) aggregated cost
structure allows the general focus of health-care cost for the population of women in their
second pregnancy when their first pregnancy resulted in a cesarean delivery.
Querying HCUPnet. Using a step-by-step query process in HCUPnet, one starts
with using national statistics, identifying oneself as a researcher, then specifying how he
or she wants to query, which is by diagnosis and procedure codes; next, the researcher
chooses a year (in this case, 2010). The next step is divided into choices for queries using
different coding systems for instance, ICD-9-CM, DRG, or CCS. For this study, the
choice of coding system varied by the clinical events and complications contingent on
codes already determined (see Tables 1- 6). Some clinical events and complications
required the use of only ICD-9-CM codes to derive cost estimates and some clinical
events and complications required ICD-9-CM codes as well as DRG and/or CCS codes.
The next selection in the HCUPnet query was for outcomes and measures which
produced statistics including number of discharges, mean length of stay (days), mean
hospital costs, percentage of deaths, and discharge status (to home, assisted living
facility, or rehabilitation, or funeral home or mortuary). The last selection was for type of
patient and hospital, which in this study was for all hospitals and all patients. This
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produced a table with weighted national estimates from 2010 HCUP NIS, based on data
collected by individual states and provided to AHRQ. When using HCUPnet with
specific ICD-9-CM codes or combination of codes no standard error is given. Statistics
based on 10 or fewer weighted cases are noted as not reliable and are suppressed. Cost
estimates for maternal deaths were not available from HCUPnet due to the low number of
cases, so these cost estimates were obtained from the peer-reviewed literature (Chung et
al., 2001 and Grobman et al., 2000).
Timing adjustments for costs. Costs that are incurred at different timeframes
need to be adjusted to ensure that all costs are based on a common year (Grey et al.,
2011). All costs estimates from HCUPnet were from 2010. Only costs estimates for
maternal death, which were taken from the peer-reviewed literature in the years 2000 and
2001, were from another year. Following the recommendation of Grey et al. (2011), the
medical consumer price index, which reflects the change in cost to the medical consumer,
was used to standardize these past cost estimates to 2010.
Effectiveness measures
Effectiveness measures what an intervention achieves in “real” world conditions
or via routine clinical practice (Rascati, 2009). When establishing effectiveness
measurements for health interventions, consideration of events that can influence the
outcomes of the population studied is necessary and effectiveness is measured in clinical
units (Rascati, 2009). The outcome or effectiveness measure utilized in the study was
length of hospital stay (LOS) in number of days. Each clinical event and complication
for the mother and baby due to an ERCD or TOL has the potential to add days to a
hospitalization. In this study, LOS is a negative effectiveness measure. That is, lower
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LOS indicates greater effectiveness and is a preferable outcome. LOS for the mother is
considered from admission of mother until she goes home. This might include the
mother’s time in labor prior to the birth, which is not always a contributing factor to her
complication event rate. LOS for the baby is considered from the birth of the baby
(admission) until he or she goes home. For this research, HCUPnet (2012) estimates were
used for length of hospital stay and obtained by the same process as for costs.
Model Inputs
By convention, model costs and probabilities are entered under the branches
emanating from the chance node. These model probabilities represent the likelihood of
uncertain maternal and baby clinical events and possible complications stemming from
the choice between ERCD and TOL. The model costs represent the cost of
hospitalization for these events. The effectiveness measure used was length of hospital
stay (see Tables 1–6).
The following sections enumerated by ERCD or TOL for the mother and baby
include definitions of possible complications, probabilities of such events, and their
calculated costs.
ERCD maternal events, possible complications, probabilities and costs.
No Complications. ERCD is defined as a woman in her second pregnancy with a
previous cesarean delivery for the first pregnancy, who is scheduling repeat cesarean
delivery at 39 weeks gestation for a set time and who is not in labor. The probability used
for “no complications” was calculated by summing up the probabilities across
complications and then subtracting from one. Median cost was calculated using ICD-9-
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CM 654.21, 669.7, CCS 134, and DRG 765 and 766 and produced a cost estimate of
$4,752. The mean LOS was 2.8 days.
Hemorrhage. Hemorrhage is defined as the loss of blood in the post-partum
period (after delivery of baby) of more than 1000 ml following a cesarean delivery
(Begley, Gyte, Devane, McGuire, & Weeks, 2011). The probability of this event was
0.024 (Chung et al., 2001; Macario et al., 2004). Median cost was calculated using ICD9-CM 666.02, 666.1, and 654.21 and produced a cost estimate of $58,067. The mean
LOS was 9.3 days.
Infection. This definition includes sepsis and uterine, urinary, pulmonary, or
wound infections (Chung et al., 2001). The probability of this event was 0.075 (Chung et
al., 2001; Macario et al., 2004). Median cost was calculated using ICD-9-CM 654.21 and
CCS 168 and produced a cost estimate of $17,526. The mean LOS was 3.2 days.
Thromboembolic event. This event is defined as a lodgment of a blood clot
causing blockage of a vein. As a rare event, this would include a deep vein thrombolysis,
pulmonary embolism, and amniotic embolism during hospitalization for delivery at term.
The base case probability for this event was 0.001 (Grobman et al., 2000) and alternate
case probability was 0.007 (Macario et al., 2004). Median cost was calculated using ICD9-CM 673.21 and produced a cost estimate of $76,132. The mean LOS was 10 days.
Operative injury. This is defined as a laceration of uterine arteries or injury to
viscera other than the uterus during the course of the operative delivery (Chung et al.,
2001). The base case probability was 0.0001 (Grobman et al., 2000) and alternate case
probability was 0.0039 (Macario et al., 2004). Median cost was calculated using ICD-9CM 674.34 and produced a cost estimate of $24,867. The mean LOS was 4.7 days
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Hysterectomy. This event is defined as an operative procedure to remove the
uterus. The base case probability of this event was 0.0014 (Cheng et al., 2011) and
alternate case probability 0.0039 (Chung et al., 2001). Median cost was calculated by
using CCS 124 + 195 and produced a cost estimate of $73,460. The mean LOS was 6.9
days.
Uterine rupture/dehiscence. Uterine rupture is defined as a defect through the
entire uterine wall that requires operative intervention. Uterine dehiscence is the
separation of a uterine wound or a uterine surgical scar. These are considered together in
this study because they are detected most often during surgery and are classified under
the same ICD-9-CM code. The base case probability of the event was 0.0014 (Landon et
al., 2004) and alternate case probability 0.0008 (Chung et al., 2001). Median cost was
calculated by using ICD-9-CM 665.11 and produced a cost estimate of $24,768. The
mean LOS was 3.7 days.
Maternal death. This event is considered at time of delivery. The base case
probability for this event was 0.0002 (Macario et al., 2004) and alternate case probability
0.0004 (Landon et al., 2004). The HCUP query using ICD-9-CM code 669.9 for maternal
sudden death produced no cases. Costs were determined by values stated in the
published literature of $2,150 (Chung et al., 2001) and $100,000 (Grobman et al., 2000),
adjusted to 2010 dollars using the medical CPI to $2,647.21 and $126,629.50,
respectively. The mean LOS by assumption was 0 days.
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Table 1. Model Input Maternal ERCD
Maternal ERCD

Codes
from
HCUPnet
(2010)
ICD-9CM654.21,
669.7,
CCS 134,
and DRG
765 and
766
ICD-9CM
666.02,
666.1,
and
654.21
ICD-9CM
654.21
and CCS
168

Base case
probability

Alternate
case
probability

Direct
Costs
Estimates

LOS
(in
days)

Source

.8969¹

.8023

$4752

2.8

Landon
2004¹

.024¹

.074²

$58,067

9.3

.075¹

.02²

$17,526

3.2

Thromboembolic
event

ICD-9CM
673.21

.001¹

.0007²

$76,132

10

Operative injury

ICD-9CM
674.34

.0001¹

.0039²

$24,867

4.7

Hysterectomy

CCS 124
+ 195

.0014¹

.0039²

$73,460

6.9

Uterine
rupture/dehiscence

ICD-9CM
665.11

.0014¹

.0008²

$24,768

3.7

Maternal Death

ICD-9CM 669.9

.0002¹

.0004²

$2,150³
0
($2,647)
&
$100,000¹
($126,629)

Macario
2004¹,
Chung
2001¹,
Hibbard
2001
Marcario
2004¹,
Chung
2001¹,
Spong
2007
Landon
2004¹,
Macario,
2004²
Grobman,
2000¹,
Macario,
2004²
Cheng,
2011¹,
Chung,
2001²
Landon,
2004¹,
Chung,
2001²
Grobman
2000¹,
Landon,
2004²,
Chung
2001³

No complication

Hemorrhage

Infection
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TOL followed by VBAC- maternal events, possible complications,
probabilities and costs.
No complications. TOL followed by a VBAC is defined as a woman in her
second pregnancy with a previous cesarean delivery for the first pregnancy who has had a
successful TOL and a vaginal birth without complications. The probability for “no
complications” was calculated by summing up the probabilities across complications and
then subtracting from one. Median cost was calculated by using ICD-9-CM, DRG, and
CCS codes (respectively) 654.21, 774, 196+189 and produced a cost estimate of $4,113.
The mean LOS was 2.8 days.
Hemorrhage. Hemorrhage is defined as blood loss with a vaginal delivery greater
than 500 ml. (Begley, Gyte, Devane, McGuire, & Weeks, 2011). The probability of this
event is 0.012 (Chung et al., 2001; Macario et al., 2004). Median cost was calculated by
using ICD-9-CM codes 666.02 and 666.1, and produced a cost estimate of $25,076. The
mean LOS was 4.1 days.
Infection. Infection is defined the same as with ERCD. The probability of this
event is 0.034 (Chung et al., 2001; Macario et al., 2004).Median cost of this event was
calculated by using ICD-9-CM and CCS codes 654.21, 168 and produced a cost estimate
of $17,526. The mean LOS was 3.2 days.
Thromboembolic event. Thromboembolic event is also defined the same as with
ERCD. The base case probability of this event is 0.0002 (Chung et al, 2001; Macario et
al., 2004) and the alternate case probability is 0.0004 (Landon et al., 2004). Median cost
was calculated by using ICD-9-CM code 671.51 and produced a cost estimate of $59,936.
The mean LOS was 7.9 days.
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Operative injury. Operative injury is defined the same as for ERCD and includes
severe vaginal lacerations. The probability of this event is 0.001 (Chung et al., 2001;
Macario et al., 2004). Median costs were calculated by using ICD-9-CM code 674.30 and
produced a cost estimate of $18,949. The mean LOS was 3.6.
Hysterectomy. Hysterectomy is defined as surgery to remove the uterus after a
successful VBAC. The base case probability of this event is 0.0002 (Chung et al., 2001)
and alternate case probability is 0.002 (Landon et al., 2004). Median cost was calculated
by using CCS code 124+195 and produced a cost estimate of $73,460. The mean LOS
was 6.9 days.
Uterine rupture/dehiscence. The definitions for uterine rupture/dehiscence are
the same as for ERCD. The base case probability of this event is 0.007 (Landon et al.,
2004) and alternate case probability is 0.0005 (Chung et al., 2001; Macario et al., 2004).
Median cost was calculated by using ICD-9-CM code 665.11 and produced a cost
estimate of $24,768. The mean LOS was 3.7 days.
Maternal death. Maternal death is defined as death of the mother at delivery. The
probability of this event is 0.00002 (Chung et al., 2001; Macario et al., 2004). ICD-9-CM
code 669.9 for maternal sudden death produced no results. Costs were determined by
values stated in the published literature of $2,150 (Chung et al., 2001) and $100,000
(Grobman et al., 2000), discounted to $2,647.21 and $126,629.50, respectively. The mean
LOS by assumption was 0 days.
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Table 2. Model Inputs Maternal TOL Followed by VBAC
Maternal TOLVBAC

Codes from
HCUPnet
(2010)
ICD-9-CM,
DRG, and
CCS codes
(respectively)
654.21, 774,
196+189
ICD-9-CM
codes 666.02,
666.1

Base case
probability

Direct Costs
Estimates

.94378¹

Alternate
case
probability
.9301

Source

$4,113

LOS
(in
days)
2.8

.012¹

.008²

$25,076

4.1

.034¹

.023²

$17,526

3.2

ICD-9-CM
code 671.51

.0002¹

.0004²

$59,936

7.9

ICD-9-CM
code 674.30
CCS code
124+195

.001¹

.001

$18,949

3.6

.0002¹

.002²

$73,460

6.9

Uterine
rupture/dehiscence

ICD-9-CM
code 665.11

.007¹

.0005²

$24,768

3.7

Maternal death

ICD-9-CM
code 669.9

.00002¹

0

$2,150
($2647.21)
$100,000
($126,629.50

0

Chung
2001¹,
Macario
2004¹,
Gregory
2008
Chung
2001¹,
Macario
2004¹,
Loebel
2004
Macario
2004¹,
Landon
2004²
Macario
2004¹
Chung
2001¹,
Landon
2004²
Landon
2004¹,
Macario
2004²
Chung
2001¹,
Macario
2004¹

Infection

ICD-9-CM
and CCS
codes 654.21,
168

Thromboembolic
event

Operative injury

No complications

Hemorrhage

Hysterectomy

TOL followed by an RCD- maternal events, possible complications,
probabilities and costs.

Landon
2004¹
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No complications. No complications is defined as the situation for a woman in
her second pregnancy with a previous cesarean delivery for the first pregnancy, who has
a TOL which results in a cesarean delivery. The probability for “no complications” was
calculated by summing up the probabilities across complications and then subtracting
from one. Median cost was calculated by using ICD-9-CM code 660.61 and produced a
cost estimate of $5,614. The mean LOS was 3.3.
Hemorrhage. Hemorrhage is defined the same as for ERCD. The probability of
this event is 0.021 (Chung et al., 2001; Macario et al., 2004). Median cost was calculated
by using ICD-9-CM codes 666.02, 666.1 and produced a cost estimate of $58,067. The
mean LOS was 9.3 days.
Infection. Infection is defined the same as for ERCD. The base case probability
of this event is 0.19 (Macario et al., 2004) and alternate case probability is 0.03
(Grobman et al, 2000). Median cost was calculated by using ICD-9-CM and CCS codes
654.21, 168 and produced a cost estimate of $17,526. The mean LOS was 3.2 days.
Thromboembolic event. Thromboembolic event is defined the same as for ERCD
and VBAC. The base case probability of this event is 0.0008 (Chung et al., 2001;
Macario et al., 2004) and the alternate case probability is 0.003 (Grobman et al., 2000).
Median cost was calculated by using ICD-9-CM code 673.21 and produced a cost
estimate of $76,132. The mean LOS was 10 days.
Operative injury. Operative injury is defined the same as for ERCD. The base
case probability of this event is 0.034 (Chung et al., 2001; Macario et al., 2004) and the
alternate case probability is 0.02 (Grobman et al., 2000). Median cost was calculated by
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using ICD-9-CM code 674.30 and produced a cost estimate of $24,867. The mean LOS
was 3.6 days.
Hysterectomy. Hysterectomy is defined the same for ERCD. The probability of
this event is 0.004 (Chung et al., 2001; Macario et al., 2004). Median cost was calculated
by using CCS code 124+195 and produced a cost estimate of $73,460. The mean LOS
was 6.9 days.
Uterine rupture/dehiscence. Uterine rupture/dehiscence is defined the same as
for ERCD. The probability of this event is 0.019 (Chung et al., 2001; Macario et al.,
2004). Median cost was calculated by using ICD-9-CM code 665.11 and produced a cost
estimate of $24,768. The mean LOS was 3.7 days.
Maternal death. This event is defined as death of the mother at delivery. The
probability of this event is 0.00017 (Macario et al., 2004). ICD-9-CM code 669.9 for
maternal sudden death produced no results. Costs were determined by values stated in the
published literature of $2,150 (Chung et al., 2001) and $100,000 (Grobman et al., 2000),
discounted to $2,647.21 and $126,629.50, respectively. The mean LOS by assumption
was 0 days.
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Table 3. Model Inputs for Maternal TOL Followed by an RCD
Maternal TOL-RCD

Codes
from
HCUPnet
(2010)
ICD-9CM code
660.61
ICD-9CM codes
666.02,
666.1,
654.21

Base case
Probability

Alternate
case
Probability

Direct
Costs
Estimates

LOS
(in
days)

Source

.731¹

.834

$5,614

3.3

Macario
2004¹

.021¹

.09²

$58,067

9.3

ICD-9CM and
CCS
codes
654.21,
168
ICD-9CM code
673.21

.19¹

.03²

$17,526

3.2

Chung
2001¹,
Macario
2004¹,
Hibbard
2001
Macario
2004¹,
Grobman
2000²

.0008¹

.003²

$76,132

10

Operative injury

ICD-9CM code
674.30

.034¹

.02²

$24,867

3.6

Hysterectomy

CCS code
124+195
ICD-9CM code
665.11

.004¹

.004¹

$73,460

6.9

.019¹

.019¹

$24,768

3.7

ICD-9CM code
669.9

.00017¹

0

$2,150¹
($2,647)
&
$100,000²
($126,629)

No complication

Hemorrhage

Infection

Thromboembolic
event

Uterine
rupture/dehiscence

Maternal death

Macario
2004¹,
Chung
2001¹,
Grobman,
2000²
Macario
2004¹,
Chung
2001¹,
Grobman
2000²
Chung
2001¹
Macario
2004¹,
Chung
2001¹
Chung
2001¹,
Grobman
2000²
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ERCD baby events, possible complications, probabilities and costs.
No complications. No complications is defined as a baby born at 39 weeks
gestation from an ERCD without complications. The probability for “no complications”
was calculated by summing up the probabilities across complications and then
subtracting from one. Median cost was calculated by using ICD-9-CM code V 30.01 and
CCS 218 and produced a cost estimate of $4,598. The mean LOS was 4.7 days.
Respiratory distress. Respiratory distress is defined as signs inclusive of
tachypnea (rapid respirations), retractions, grunting, nasal flaring, and cyanosis on room
air, or requiring treatment with any of the following: supplemental oxygen, nasal
continuous positive pressure, endotracheal intubation, or exogenous surfactant (Yee et al.,
2008). The base case probability of this event is 0.059 (Kamath et al., 2009) and the
alternate case probability is 0.10 (Yee et al., 2008). Median cost was calculated by using
ICD-9-CM codes V30.01, 770.89 and produced a cost estimate of $63,588. The mean
LOS was 10.9 days.
Sepsis. Sepsis is defined as the immune system’s reaction to a serious infection.
In an infant, the symptoms may involve the respiratory, gastrointestinal and central
nervous systems. Sepsis is most often confirmed by bacteria found in a blood culture
(Deluca et al., 2009). The probability of this event is 0.02 (Hook et al., 1997). Median
cost was calculated by using ICD-9-CM codes V30.01, 771.81 and produced a cost
estimate of $19,706. The mean LOS was 9.5 days.
Hypoxic Ischemic Encephalopathy (HIE). HIE is defined as an injury to the
brain thought to be caused by hypoxia during the birth (Go et al., 2011). The base case
probability of this event is 0.0032 (Gregory et al., 2008) and the alternate case probability
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was 0 (Landon et al., 2004). Median cost was calculated by using ICD-9-CM codes
V30.01, 768.73 and produced a cost estimate of $63,891. The mean LOS was 24.7 days.
Neonatal death. Neonatal death is defined as the death of a baby who is born live,
and then dies (Go et al., 2011). The probability of this event is 0.0005 (Landon et al.,
2004) and alternate probability is 0.0008 (Menacker et al., 2010). The cost was calculated
by using ICD-9-CM codes V 30.01, 656.41 and produced a cost of $4,626. The mean
LOS by assumption was 0.
Table 4. Model Input Baby-ERCD
Baby-ERCD

Base case
Probability

Alternate
case
Probability

Direct
Costs
Estimates

LOS (in
days)

Source

No
complication

Codes
from
HCUPnet
(2010)
V 30.01
CCS-218

.9173¹

.860

$4,598

4.7

Kamath
2009¹

Respiratory
distress

V 30.01
770.89

.059¹

.10²

$63,588

10.9

Sepsis

V 30.01
771.81

.02¹

.027²

$19,706

9.5

HIE

V 30.01
768.73

.0032¹

0²

$63,891

24.7

Neonatal
death

V 30.01
656.41

.0005¹

.0008²

$4,626

0

Kamath
2009¹,
Patel 2010²
Hook
1997¹,
Loebel
2004²
Gregory
2008¹,
Landon
2004²
Landon
2004¹,
Menacker
2010²

TOL followed by a VBAC baby events, possible complications, probabilities
and costs.
No complications. No complications is defined as a normal baby born without
complications to a woman who has had a cesarean delivery with her first pregnancy, and
delivered vaginally. The probability for “no complications” was calculated by summing
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up the probabilities across complications and then subtracting from one. Median cost
was calculated by using ICD-9-CM code V 30.00 and produced a cost estimate of $1,975.
The mean length of stay was 2.5 days.
Respiratory distress. Respiratory distress is defined the same as for ERCD. The
probability of this event is 0.012 (Kamath et al., 2009). Median cost was calculated by
using ICD-9-CM codes V30.00, 770.89 and produced a cost estimate of $63,588. The
mean LOS was 10.9 days.
Sepsis. Sepsis is defined the same as for ERCD. The probability of this event is
0.02 (Go et al., 2011). Median cost was calculated by using ICD-9-CM codes V30.00,
771.81 and produced a cost estimate of $19,706. The mean LOS was 9.5 days.
HIE. HIE is defined the same as for ERCD. The probability of this event is
0.0008 (Spong et al., 2007). Median cost was calculated by using ICD-9-CM codes
V30.00, 768.73 and produced a cost estimate of $63,891. The mean LOS was 24.7.
Neonatal death. Neonatal death is defined the same as for ERCD. The
probability of this event is 0.0006 (Manacker et al., 2010). Median cost was calculated by
using ICD-9-CM codes V30.00, 656.41 and produced a cost estimate of $4,626. The
mean LOS was by assumption 0 days.
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Table 5. Model Input Baby TOL-VBAC
Baby-TOLVBAC

Codes
from
HCUPnet
(2010)
V 30.00

Base case
Probability

Alternate
case
Probability

Direct
Costs
Estimates

LOS (in
days)

Source

.9665¹

.961

$1,975

2.5

Kamath
2009¹

Respiratory
distress

V 30.00
770.89

.012¹

none

$63,588

10.9

Kamath
2009¹

Sepsis

V 30.00
771.81

.02¹

.12²

$19,706

9.5

HIE

V 30.00
768.73
V 30.00
656.41

.0008¹

none

$63,891

24.7

.0007¹

none

$4,626

0

Go 2011¹,
Hook
1997²
Spong
2007¹
Menacker
2010¹

No
complication

Neonatal
death

TOL followed by a RCD baby events, possible complications, probabilities
and costs.
No complications. No complications is defined as a baby born without
complications to a mother who had a cesarean for her first delivery and then had a TOL
that resulted in another cesarean delivery. The probability for “no complications” was
calculated by summing up the probabilities across complications and then subtracting
from one. Median cost was calculated by using ICD-9-CM codes V30.01, and produced
a cost of $4,598. The mean LOS was 4.7.
Respiratory distress. Respiratory distress is defined the same as for ERCD. The
probability of this event is 0.059 (Kamath et al., 2009). Median cost was calculated by
using ICD-9-CM codes V30.01, 770.89 and produced a cost estimate of $63,588. The
mean LOS was 10.9.
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Sepsis. Sepsis is defined the same as for ERCD. The probability of this event is
0.12 (Patel & Jain, 2010). Median cost was calculated by using ICD-9-CM codes V30.01,
771.81 and produced a cost estimate of $19,706. The mean LOS was 9.5 days.
HIE. HIE is defined the same as for ERCD. The probability of this event is 0
(Spong et al, 2007). Median cost was calculated by using ICD-9-CM codes V30.01,
768.73 and produced a cost estimate of $63,891. The mean LOS was 24.7 days.
Neonatal death. Neonatal death is defined the same as for ERCD. The
probability of this event is 0.0009 (Spong et al., 2007). Median cost was calculated by
using ICD-9-CM codes V30.01, 656.41 and produced a cost estimate of $4,698. The
mean LOS by assumption was 0.

Table 6. Model Inputs Baby-TOL-RCD
Baby-TOLRCD
No
complication
Respiratory
distress
Sepsis

HIE
Neonatal
death

Codes from
HCUPnet
(2010)
V30.01

Base case
Probability

Direct
Cost
Estimates
$4,598

LOS (in
days)

Source

.8201¹

Alternate
case
Probability
.820

4.7

V30.01
770.89
V 30.01
771.81

.059¹

none

$63,588

10.9

.12¹

.02²

$19,706

9.5

V30.01
768.73
V30.01
656.41

0¹

none

$63,891

24.7

.0009¹

.0011¹

$4,626

0

Kamath
2009¹
Kamath
2009¹
Patel
2010¹,
Hook
1997²
Spong
2007¹
Spong
2007¹

Calculation of Cost-Effectiveness.
Cost-effectiveness analysis involves a “numerical estimate of magnitude of effect
of an intervention on health outcome” (Mandelblatt et al., 1996, p. 135). When an
intervention under study is both more effective and less costly than the alternative, it is
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said to dominate the alternative. The presentation of cost-effectiveness results includes
calculating average cost-effectiveness ratios (ACER, Grey et al., 2011) and incremental
cost-effectiveness ratios (ICER). These ratios can help answer clinical practice
dilemmas. When one of the interventions is more expensive and more effective than the
other, the ICER is used to decide the extent of the added cost for each unit in health
improvement. When the ICER, used as the difference in the cost divided by the
difference in effectiveness, yields a negative number, this designates that one
intervention, the dominant option, is both more effective and less expensive than the
other, dominated option (Rascati, 2009).
Cost-effectiveness calculations can be depicted as the comparison of alternatives
in a graph. This graph takes place in the north-east portion of the cost-effectiveness plane.
When one alternative or intervention is dominated by the other it is more expensive and
less effective. The slope of the line between the two alternatives represents the ICER. In
this study, there will appear to be a positive slope between dominated alternatives in the
cost-effectiveness graph due to the use of a negative effectiveness measure.
Average cost-effectiveness ratio. The ratio of cost to effectiveness for a single
treatment gives a comparison that is made “in relation to doing nothing or no treatment,”
this is referred to as an ACER (Gray et al., 2011, p. 14; Rascati, 2009, p. 48). For this
research, an ACER would be, for example, calculated by dividing cost for the mother for
ERCD by LOS for the mother for ERCD (cost/LOS). The benefit of doing this
calculation is that it shows the cost and effectiveness (cost per one unit of effectiveness)
of each intervention alone.
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Incremental cost-effectiveness ratio (ICER). An ICER, as used in health
services research, compares the differences between cost and health outcomes of two
alternative interventions that compete for the same resources. ICERs generally describe
the additional cost per additional health outcome (Grey et al., 2011). When using a
negative effectiveness measure, it is useful to calculate the negative of the usual ICER for
comparative purposes.
The numerator in the ICER represents the difference between the cost of the two
interventions being compared (the net cost). In this study, the numerator used was cost of
ERCD minus cost of TOL. The denominator is the difference in effectiveness between
these two interventions (the net effectiveness). The net effectiveness of the intervention
is an estimated difference in outcomes related to a health state that may occur as a
consequence of the intervention and its alternative (Rascati, 2009). The health-related
outcome used as a measure of effectiveness in this study was length of hospital stay, so
the denominator for the ICER was the length of stay for ERCD minus the LOS for TOL.
Formulas for the ICERs for mother and baby are shown below (see Figure 3).
CostA  CostB
EffectA  EffectB
Mother





CostA  CostB
EffectA  EffectB
Baby





Figure 3. ICERs for mother and baby.
Sensitivity Analysis
Sensitivity analysis is performed using selected uncertain parameters of a decision
analysis model to test whether the results of a cost-effectiveness analysis would change

93
based on changing the values of the uncertain parameter. One-way sensitivity analyses
were performed in this study to bring critical focus to important uncertain parameters
related to maternal complications, including cost of maternal mortality and the
probabilities of thromboembolic event, hemorrhage, and infection. In addition, one-way
sensitivity analyses were performed for the baby for the probabilities of complications of
respiratory distress syndrome, sepsis, and neonatal mortality.
As an example, cost estimates for maternal mortality based on the costs of one
day in an intensive care unit ranged from $2,150 (Chung et al., 2001) to $100,000
(Grobman, 2000). Such a wide variation could change the outcome of the costeffectiveness analysis. Thus, these values were used as base case and alternate case
estimates.
Additional sensitivity analyses were performed using estimates of maternal LOS
for uncomplicated ERCD of 3.92 days and uncomplicated VBAC of 2.55 days reported
by Guise et al., (2010). These estimates varied from 2010 HCUPnet (2012) estimates for
uncomplicated ERCD of 2.8 days and uncomplicated VBAC of 2.8 days. Changes in
estimated values for these key outcomes could change the outcome of the costeffectiveness analysis.
This analysis was presented in table format with the value of each probability or
cost varied compared for each strategy, ERCD or TOL. The subsequent columns in each
table are for costs, net incremental costs, effectiveness (LOS), and net incremental
effectiveness. The final columns in each table are for ACERs and ICERs. When
parameter estimates in a sensitivity analysis are varied, the assumptions of the decision
model must be maintained. In particular, the probabilities need to always add to one. In
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this study, probabilities for uncomplicated ERCD, RCD, and VBAC were adjusted as
other probabilities varied in order to maintain this assumption.
Summary
Haddix et al. (2003) specified the core elements of a decision analysis as follows:
(a) specify a decision problem or objective, (b) structure a decision model, (c) estimate
probabilities, (d) value consequences (outcomes), (e) analyze the base case, and (f)
evaluate uncertainty (sensitivity analyses). These components of a decision analysis were
defined in this chapter. This chapter also included detailed explanations of queries
performed in HCUPnet, figures derived from TreeAge for the decision analysis for
mother and baby. It includes tables that display model inputs, including codes and
categories used to derive estimates for costs and LOS and probabilities taken from peerreviewed literature.
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Chapter 4
Results
The first objective of this study was to establish probabilities for possible events
and complications for ERCD and TOL in a second pregnancy. The second objective was
to determine the cost and effectiveness (LOS) associated with each procedure, ERCD and
TOL. Tables 1–6 display probabilities for the mother and baby from peer-reviewed
published literature, as well as costs, and effectiveness (LOS) measures calculated from
HCUPnet (2012) from the year 2010. The third objective was to calculate the ICER
between ERCD and TOL for the mother and baby. This chapter includes those results.
The first section provides study findings for the mother from the costeffectiveness analysis comparing ERCD and TOL. The second section presents the same
information for the baby. Subheadings for each section are cost-effectiveness comparing
ERCD and TOL, incremental cost-effectiveness ratio, and sensitivity analysis.
For the Mother
Cost-Effectiveness Comparing ERCD and TOL
Figure 4 displays the decision analysis including probabilities, costs, and LOS for
base case scenarios in decision tree format comparing ERCD and TOL in a second
pregnancy for the mother. Figure 5 displays the results of the cost-effectiveness analysis
comparing ERCD and TOL in a second pregnancy for the mother. In general, TOL was
found to the preferred option over ERCD in a second pregnancy. Specifically, of the
possible modes of delivery, TOL was the most preferred overall at $6,388.07\3.0
(Cost\LOS).
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Figure 4. Mother decision tree.
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Figure 5. Maternal cost-effectiveness analyses.
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Incremental Cost-Effectiveness Ratio
Figure 6 displays a graphical plot of cost and effectiveness for the base case
results of the cost-effective analysis comparing ERCD and TOL in a second pregnancy
for the mother. ERCD is dominated by TOL because costs of ERCD are higher and
effectiveness is lower. The lower effectiveness is reflected in higher LOS graphically.
TOL was the cost-effective alternative.

Figure 6. Cost-Effectiveness Graph using Base Case Probabilities for CostEffectiveness Analysis Comparing ERCD and TOL in a Second Pregnancy.
Table 7 displays base case results for incremental cost-effectiveness comparing
ERCD and TOL in a second pregnancy for the mother. The ACER reflects the cost per
one unit of effectiveness (LOS), which were $2,132.48/day for TOL and $2395.73/day
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for ERCD. The ICER, as defined in Figure 4, is the negative of the ratio of the difference
in costs between ERCD and TOL to the difference in effectiveness between ERCD and
TOL. In this case, $7,186.79 minus $6,388.13 divided by 2.9996 minus 2.956 leads to an
incremental cost difference of $798.66 and incremental effectiveness of .0042. ERCD
was dominated by TOL. The incremental cost-effectiveness ratio between ERCD and
TOL was -$190,501.76/LOS. This negative ICER is consistent with dominance, and
hence, cost-effectiveness.
Table 7. Cost-Effectiveness Comparing ERCD and TOL for the Mother in a Second Pregnancy
Strategy

Cost

TOL

$6,388.13

ERCD

$7,186.79

Incremental
Cost

LOS
(Eff)

Incremental
Eff (LOS)

ICER

2.9956
$798.66

2.9998

C/E
(ACER)
$2,132.48

0.0042

-$190,501.76

$2,395.73

Sensitivity Analysis
A one-way sensitivity analysis was performed to bring critical focus to the
selected uncertain probability estimates from the peer-reviewed literature of
thromboembolic events for ERCD and RCD; infection for ERCD, RCD and VBAC; and
hemorrhage for ERCD, RCD and VBAC. Cost estimates were varied for maternal
mortality for ERCD, RCD, and VBAC. Table 8 includes base case probabilities and the
alternative case probabilities for each strategy. Table 9 includes the varied cost estimates
for maternal mortality. Subsequent columns of these tables represent costs of the strategy,
incremental costs, effectiveness (LOS), and incremental effectiveness. The final
calculations are the ACER (C/E) and the ICER for each parameter estimate varied.
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Table 8. Sensitivity Analysis: Cost-Effectiveness Analysis Comparing ERCD and TOL in a
Second Pregnancy Applying Base Case and Alternative Probabilities Maternal Values
Probability Strategy
varied
Hem-E
0.024*
TOL
ERCD
0.074
TOL
ERCD
Hem-RCD
0.021*
TOL
ERCD
0.09
TOL
ERCD
Hem-VB
0.008
TOL
ERCD
0.012*
TOL
ERCD

Inf-ERCD
0.02
0.075*
Inf-RCD
0.03
0.19*
Inf-VBAC
0.023
0.034*

Cost

$6,388.13
$7,186.79
$6,388.13
$9,852.54
$6,388.13
$7,186.79
$7,329.14
$7,186.79
$11,591
$7,186.79
$6,388.13
$7,186.79

TOL
ERCD
TOL
ERCD

$6,388.13
$7,889.36
$6,388.13
$7,186.79

TOL
ERCD
TOL
ERCD

$6,422.20
$7,186.79
$6,388.13
$7,186.79

TOL
ERCD
TOL
ERCD

$11,591
$7,186.79
$6,388.13
$7,186.79

Incr Cost

Eff

2.9956
2.9998
2.9956
$3,464.41 3.3248
$798.66

$798.66
$142.35

2.9956
2.9998
3.1076
2.9998

3.0038
$4,404.21 2.9998
2.9956
$798.66
2.9998

$1501.23
$798.66

$764.59
$798.66

2.9956
3.1528
2.9956
2.9998
2.9997
2.9998
2.9956
2.9998

3.0000
$4,404.21 2.9998
2.9956
$798.66
2.9998

Incr Eff ACER

-0.0042
-0.325

-0.0042
-0.1078

-0.004
-0.0042

-0.154
-0.0042

-0.0001
-0.0042

-0.0002
-0.0042

$2,132.48
$2,395.93
$2,132.48
$2,963.34
$2,132.48
$2,395.93
$2,388.11
$2,395.93
$3,858.78
$2,395.93
$2,132.48
$2,395.93

$2,132.48
$2,502.34
$2,132.48
$2,395.93
$2,140.95
$2,395.93
$2,132.48
$2,395.93
$3,863.67
$2,395.93
$2,132.48
$2,395.93

ICER

-$190,502
-$10,660

-$190,502
-$1,320.50

-$1,101,053
-$190,502

-$68,238
-$190,502

-$7,645,900
-$190,502

-$22,021,050
-$190,506
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Table 8. Continued
Probability Strategy
varied
Throm-E
0.00
TOL
ERCD
0.001*
TOL
ERCD
Throm-RC
0.0
TOL
ERCD
0.0008*
TOL
ERCD

Cost

$6,388.13
$7,186.79
$6,388.13
$7,258.17
$6,402.80
$7,186.79
$6,388.13
$7,186.79

Incr Cost

$798.66
$870.04

$783.99
$798.66

Eff

2.9956
2.9998
2.9956
2.9926
3.0014
2.9998
2.9956
2.9998

Incr Eff

-0.0042
-0.0072

-0.0016
-0.0042

ACER

$2,132.48
$2,395.93
$2,132.48
$2,425.37
$2,133.27
$2,395.93
$2,132.48
$2,395.93

ICER

-$190,502
-$120,839

-$489,994
-$190,502

Hem-E- hemorrhage ERCD
Hem-VB-hemorrhage VBAC
Throm-E- Thromboembolic event ERCD
Throm-RC- Thromboembolic event RCD
*Base case
Table 9. Sensitivity Analysis: Cost-Effectiveness Analysis Comparing ERCD and TOL in a
Second Pregnancy Applying Base Case and Alternative Costs for Maternal Values
Cost varied
Mat mort
$2,647.00*
$126,629.00

Strategy

Cost

TOL
ERCD
TOL
ERCD

$6,388.13
$7,186.79
$6,388.13
$7,186.79

Incr cost

$798.66
$798.66

Eff

2.9956
2.9998
2.9956
2.9998

Incr
eff

-.0042
-.0042

ACER

$2,132.48
$2,395.73
$2,132.48
$2,395.73

ICER

-$190,502
-$190,502

Mat mort- Maternal mortality
*Base case
The findings from this one-way sensitivity analysis were that varying the
parameter uncertainties did not affect the overall outcome of the cost-effectiveness
analysis for the mother. For instance, increasing the probability of hemorrhage in an
ERCD by 0.05 increased the cost estimate to $9,852.54, increased the incremental cost to
$3,464.41, increased the LOS to 3.32 days, and increased the incremental effectiveness to
0.325. ERCD continued to be dominated by TOL; whereas, increasing the probability of
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hemorrhage in a VBAC by .004 increased the cost estimate to $11,591, increased the
incremental cost to $4,404.21, increased the LOS to 3.00 days, and the incremental
effectiveness remained the same at 0.004. ERCD continues to be dominated by TOL.
Therefore, the results of this cost-effectiveness analysis remain insensitive to the
parameter uncertainties applied and are proven robust.
A two-way sensitivity analysis was performed to bring critical focus to the
selected uncertain probability estimates of LOS for ERCD and TOL (see Table 10).
Changing the effectiveness rate (LOS) to the reported values used by Guise et al. (2010)
in a two-way sensitivity analysis revealed the model to be insensitive to varying the
parameters. ERCD continues to be dominated by TOL. Therefore, the model is robust.
Table 10. Two-Way Sensitivity Analysis: Cost-effectiveness Analysis comparing ERCD
and TOL in a Second Pregnancy varying LOS for Maternal Values
Effectiveness Strategy
varied
LOS
TOL
ERCD

Cost

Incr cost

$6,388.13
$7,186.79 $798.66

Eff

2.55
3.92

Incr
eff

1.37

ACER

ICER

$2,50515
$1833.36

-$582.46

For the Baby
Cost-Effectiveness Comparing ERCD and TOL
Figure 7 displays the decision analysis, including probabilities, costs, and LOS for
base case scenarios in the decision tree format comparing ERCD and TOL in a second
pregnancy for the baby. Figure 8 displays the results of the cost-effectiveness analysis
comparing ERCD and TOL in a second pregnancy, also for the baby. In general, TOL
was found to be the preferred intervention over ERCD in a second pregnancy.
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Specifically, of the possible modes of delivery, TOL was the most preferred strategy
overall at $4,883.77\3.49 (Cost\LOS).
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Figure 7. Baby decision tree.
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Figure 8. Baby cost-effectiveness analyses.
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Incremental Cost-Effectiveness Ratios
Figure 9 displays a graphical plot of cost and effectiveness for the base case
results of the cost-effective analysis comparing ERCD and TOL in a second pregnancy
for the baby. ERCD is dominated by TOL because costs of ERCD are higher and
effectiveness is lower. The lower effectiveness is reflected in higher LOS graphically.
TOL is the cost-effective alternative.

Figure 9. Cost-effectiveness graph for baby.
Table 11 displays base case results for incremental cost-effectiveness comparing
ERCD and TOL in a second pregnancy for the baby. ERCD was dominated by TOL.
ACER reflected the cost per one unit of effectiveness (LOS), TOL $1,393.31/day and
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ERCD $1,640.44/day. The ICER, as defined in Figure 3, is the negative of the costs of
ERCD minus TOL to the difference of effectiveness of ERCD minus TOL. In this case,
$8,570.32 minus $4,883.72 divided by 5.22 minus 3.49 leading to an incremental cost of
$3,686.60 and incremental effectiveness of 1.74 days. ERCD was dominated by TOL.
The incremental cost-effectiveness ratio was -$2,120.55/LOS. This negative ICER is
consistent with dominance, and hence, cost-effectiveness.
Table 11. Incremental Cost-Effectiveness for Baby

Strategy

Cost

TOL
ERCD

$4,883.72
$8,570.32

Incremental LOS
Cost
(Eff)
3.49
$3,686.60
5.22

Incremental ICER
LOS
-1.74

-$2,120.55

C/E
(ACER)
$1,401.00
$1,640.44

Sensitivity Analysis
A one-way sensitivity analysis was performed to bring critical focus to the
specific uncertain parameters, which varied the probabilities from the peer-reviewed
literature for respiratory distress syndrome ERCD, sepsis ERCD, sepsis VBAC, sepsis
RCD, neonatal mortality ERCD, and neonatal mortality RCD. Table 12 includes base
case probabilities and the alternative case probability for each strategy. Subsequent
columns represent costs of the strategies, incremental costs, effectiveness (LOS), and
incremental effectiveness. The final columns are the calculations for the ACER (C/E) and
the ICER based on variations for each parameter uncertainty.
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Table 12. Sensitivity Analysis: Cost-Effectiveness Analysis Comparing ERCD and TOL in a
Second Pregnancy Applying Base Case and Alternative Probabilities Baby Values
Probability
varied

Strategy

Cost

Incr Cost

Eff

Incr

ACER

ICER

Eff
RDS-E
0.059
0.1
Sepsis-E
0.02
0.027
ND-E
0.0005
0.0008
ND-RCD
0.0009
0.0011
Sepsis-RC
0.02
0.12
Sepsis-VB
0.02
0.12

TOL
ERCD
TOL
ERCD

$4,883.72
$8,570.32
$4,483.72
$10,988.91

TOL
ERCD
TOL
ERCD

$4,883.72
$8,570.32
$4,883.22
$8,676.08

TOL
ERCD
TOL
ERCD

$4,883,22
$8,570.32
$4,883.22
$8,570.32

TOL
ERCD
TOL
ERCD

$4,883.72
$8,570.32
$4,883.72
$8,570.32

TOL
ERCD
TOL
ERCD

$$,490.91
$8,570.32
$4,883.72
$8570.32

TOL
ERCD
TOL
ERCD

$4,883.72
$8,570.22
$6,195.81
$8,570.32

$3,686.60
$6,105.19

$3,686.60
$3,792.36

$3,686.60
$3,686.61

$3,686.60
$3,686.60

$4.079.41
$3,686.60

$3,686.60
$2,374.51

3.49
5.22
3.49
5.48
3.49
5.22
3.49
5.26
3.49
5.22
3.49
5.22
3.49
5.22
3.49
5.22
3.36
5.22
3.49
5.22
3.49
5.22
4.00
5.22

1.74
1.99

1.74
1.77

1.74
1.74

1.74
1.74

1.86
1.74

1.74
1.22

$1,401.00
$1,640.44
$1,401.00
$2,005.78
$1,401.00
$1,640.44
$1,401.00
$1,650.07
$1,401.00
$1,640.44
$1,401.00
$1648.88
$1401.00
$1,640.44
$1401.09
$1,640.44
$1,336.15
$1,640.44
$1,401.00
$1,640.44
$1,40.00
$1,640.44
$1,547.45
$1,640.44

-$2120.55
-$3063.75

-$2,120.55
-$2,140.20

-$2120.55
-$2,122.27

-$2,120.55
-$2,120.25

-$2,189.33
-$2,120.55

-$2,120.55
-$1,945.49

RDS-E-respiratory distress syndrome ERCD
ND-E-neonatal death ERCD
ND-RCD-neonatal death RCD
Sepsis-RC- sepsis RCD
The findings from this one-way sensitivity analysis were that varying the
parameter uncertainties did not affect the overall outcome of the cost-effectiveness
analysis. For instance, increasing the probability of respiratory distress in an ERCD by
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0.41 increased the cost estimate to $10,988.91, increased the incremental cost to
$6,105.19, LOS to 5.48, and incremental effectiveness to 1.99. ERCD continued to be
dominated by TOL; whereas, decreasing the probability of sepsis in a RCD by 0.10
increased the cost estimate to $4,440.91, increased the incremental cost to $4,079.41,
LOS to 3.36, and incremental effectiveness to1.86. ERCD continues to be dominated by
TOL. Therefore, the results of this cost-effectiveness analysis remain insensitive to the
parameter uncertainties applied and are robust.
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Chapter 5
Discussion
This chapter is divided into six sections. The first section provides a brief
overview of the study problem. The second section includes a recap of the study’s
findings in terms of the research objectives of establishing probabilities of complications,
determining costs, determining outcomes (LOS), and calculating incremental costeffectiveness ratios for ERCD and TOL for mother and baby. This chapter ends by
considering this study’s implications for practice, policy, and research.
Background of the Problem
As noted in the Introduction, cesarean deliveries are the most common surgical
procedure in the United States, totaling 1.5 million childbearing women in 2010 (Guise et
al., 2010). One-third of normal, low-risk first pregnancies result in cesarean deliveries
(Zhang et al., 2010). For most of the 20th century, providers thought that once a woman
had a cesarean delivery, all her future pregnancies would also end the same way (Guise et
al., 2010). Cesarean deliveries cost more than $8 billion annually and account for more
than half of childbirth-related hospitalization expenses (Guise et al., 2010).
Cost-effectiveness analysis is an important tool for comparing therapies based on
their effectiveness and costs (Gold et al., 1996; Rascati, 2009; Siegal, 2005). Using a
cost-effectiveness analysis enhances the ability of health-care providers, administrators,
and policymakers to allocate health-care resources in a systematic rather than intuitive
manner. An increasing number of both administrators and insurers in public and private
health-care systems in the US are utilizing cost-effectiveness analysis to make their
coverage decisions (Siegal, 2005).
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The literature search for this study found that only a few researchers compared the
cost-effectiveness of ERCD and TOL. Much of the current published literature related to
cesarean deliveries focuses on safety, demographics, geographic differences, and clinical
management issues, but little has been published on the overall economic consequences
of ERCD (Cunningham et al., 2010, Guise et al., 2010). Peer-reviewed articles describe a
few studies on the economic consequences of repeat cesarean deliveries compared to
VBAC from the perspectives of the health-care payer or the woman and her family (Clark
et al., 2000; Chung et al., 2001; DiMaio et al., 2002; Grobman et al., 2000; Macario et al.,
2004). To date, to my knowledge, no researcher has compared cost-effectiveness for
ERCD and TOL in a second pregnancy and their possible complications to the mother
and baby from the perspective of the health-care payer. This research filled that
knowledge gap by completing the following research objectives:
1. Establish the probabilities of complications incurred by the mother and baby for
ERCD and TOL in a second pregnancy.
2. From the perspective of the payer, determine the cost associated with ERCD and
TOL by the mother and the baby in a second pregnancy.
From the perspective of the payer, determine the outcomes (length of stay)
associated with ERCD and TOL by the mother and the baby in a second
pregnancy.
3. Determine and calculate an incremental cost-effectiveness ratio for ERCD and
TOL for the mother and baby in the second pregnancy.

Recap of Study Findings
This section discusses the findings of this study, which compared the costeffectiveness of ERCD and TOL for the mother and baby in a second pregnancy when
the first pregnancy resulted in a cesarean delivery.
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Research Objective 1 – Probability Estimates
Probability estimates for the maternal and baby event pathways were assigned
using peer-reviewed literature (DeLuca et al., 2009; Go et al., 2011; Hibbard et al, 2001:
Hook et al., 1997; Kamath et al., 2009; Landon et al., 2004; Levine et al. 2001; Menacker
et al., 2010; O’Shea et al., 2010; Patel & Jain, 2010; Spong et al., 2007; Yee et al., 2008)
(see Tables 1–6). The most likely complications for mothers across delivery types were
hemorrhage and infection, and the probability of maternal operative injury was notably
higher for RCD then for ERCD or VBAC. Complications were notably higher for RCD
than for ERCD or VBAC.
Research Objective 2 – Costs
Cost estimates were derived from HCUPnet (2012) for the year 2010, except for
maternal mortality, for which the estimates came from the peer-reviewed literature
(Chung et al., 2001; Grobman et al., 2000). The calculated average cost to the healthcare payer of an ERCD for the mother and baby were $7,187 and $8,570, respectively.
The calculated average cost to the health-care payer for a TOL for the mother and baby
were $6,388 and $4,884, respectively. The maternal costs calculated for this study were
in the range reported in the published literature, which varied from a low of $2,600
(Clark et al., 2000) to a high of $7,700 (Macario et al., 2004). The peer-reviewed
literature between 2000 and 2012 lacks any data on costs associated with the baby. These
cost estimates are presented in Tables 1–6. The most costly complications for the mothers
were the relatively rare occurrences of hysterectomy and thromboembolic events. For
babies, the most costly complications were respiratory distress and hypoxic ischemic
encephalopathy.
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Research Objective 2 – Effectiveness Outcomes
The outcome of interest, length of hospital stay, was determined using HCUPnet
(2012) data for the year 2010. The calculated average LOS for an ERCD for the mother
and the baby were 3 and 5.22 days, respectively. The calculated average LOS for a TOL
for the mother and baby, were 3 and 3.49 days, respectively. These results were in
contrast to maternal LOS estimates from Guise et al. (2010), who reported LOS for
ERCD was 3.92 days and for TOL was 2.55 days. LOS estimates for the baby have no
comparison in the peer-reviewed literature. These effectiveness estimates are presented in
Tables 1–6.
Across delivery types, the complication associated with the longest length of stay
for the mothers was a thromboembolic event, and as expected, length of stay for this
event was higher for a cesarean delivery than for a VBAC. For babies, hypoxic ischemic
encephalopathy was associated with the longest length of stay.
Research Objective 3 – Cost-Effectiveness Determination
The average and incremental cost-effectiveness ratios were calculated by
comparing ERCD and TOL separately for the mother and the baby. TOL dominated
ERCD in all scenarios. This means that the results of the cost-effectiveness analysis
established that a TOL was more cost effective than an ERCD for the mother and the
baby. These cost-effectiveness calculations are presented in Table 7.
Sensitivity Analysis
Sensitivity analyses were conducted for selected uncertain probability estimates
from the peer-reviewed literature (Cheng et al., 2011; Chung et al., 2001; Grobman et al.,
2000; Hibbard et al., 2001; Landon et al., 2004; Macario et al., 2004). The findings from
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the one-way sensitivity analyses for the mother and baby did not affect the overall
outcome of the cost-effectiveness analysis. Varying the possible event probabilities,
which at times increased the LOS, did not affect the model’s integrity. Hence, the model
remained robust.
A two-way sensitivity analysis was also conducted by varying the outcome data,
LOS. Varying LOS for both an ERCD and a TOL did not affect the model’s integrity,
further demonstrating the robustness of the model.
Comparison to Previous Literature
Peer-reviewed literature includes studies on the economic consequences of repeat
cesarean deliveries compared to TOL from the perspectives of the health-care payer or
the woman and her family (Chung et al., 2001; Clark et al., 2000; DiMaio et al., 2002;
Grobman et al., 2000; Macario et al., 2004).
Chung et al. (2001), Clark et al. (2000), and Macario et al. (2004), using
hypothetical populations of women when performing their cost-effectiveness analyses,
demonstrated a TOL without complications to be more cost-effective than an ERCD for
the mother. DiMaio et al. (2002) and Grobman et al. (2000) used, in addition, neonatal
morbidity and mortality as their outcome measures, reporting a TOL without
complications to be more cost-effective than an ERCD for mother and baby. Notably,
Clark et al., Chung et al., DiMaio et al., and Grobman et al. restricted their perspectives
by using cost estimates from their own health-care facilities.
While the main findings of this study were broadly consistent with the work of
previous authors on this topic (Chung et al., 2001; Clark et al., 2000; DiMaio et al., 2002;
Grobman et al., 2000; Macario et al., 2004), this study adds to the literature by using
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national data from 2010 on costs and outcomes derived from HCUPnet (2012).
Moreover, using the perspective of the health-care payer versus a single health-care
system allows for greater generalizability. Also, considering costs and outcomes for the
babies alongside those for the mothers, as was done in this study, produces a more
comprehensive view of the cost-effectiveness of ERCD versus TOL than was possible in
earlier studies, which lacked cost and outcomes for the babies.
Limitations
As with any research study, this dissertation has several limitations. The major
ones pertain to the HCUPnet (2012) data, cost-effectiveness analysis assumptions,
probability determinations, physician idiosyncratic coding practices, and determination of
effectiveness measure.
Limitations due to HCUPnet Data
Using HCUPnet (2012) data, presents several limitations. First, although using
summary HCUPnet data for cost estimates enhances national generalizability in regard to
cost estimates for ERCD and TOL, this summary data also limits generalizability because
the researcher is not able to drill down into subgroups such as race, ethnicity, and specific
insurance plans. This limitation restricted the breadth and depth of potential analysis,
which could have been enhanced if the full National Inpatient Sample data set were
analyzed using SPSS or similar software, which may, moreover, have allowed for the
calculation of the probabilities directly from the primary data. Second, using only one
year’s cost estimates additionally limited what might be found with a longitudinal view
of cost estimates for each of these alternatives. Finally, HCUP (2012) contains only
hospital data. It lacks fees for inpatient providers, radiology and pharmacy, and
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laboratory work costs. Because of this, the costs determined in this study are not the total
direct costs.
Limitations due to Cost-Effectiveness Analysis Assumptions
A cost-effectiveness analysis is traditionally performed when there is a real choice
between two treatment options or procedures. A woman whose first pregnancy resulted in
a cesarean delivery has a choice with her second pregnancy as to mode of delivery when
she presents with a low-risk term pregnancy and has no risk factors. Some delivery
settings do not offer TOL due to lack of necessary staff and availability of their facility
for emergency deliveries. Most often these restraints are in rural areas. This is a
preference-sensitive decision, meaning a woman has a choice between an ERCD and a
spontaneous TOL. A decision analysis about costs of one choice versus the other adds
important information to this decision and is most accurate when the following conditions
are met: decision-tree structure truly represents the alternative approach, probabilities of
occurrence of chance actions are accurate, and final consequences or outcomes are
considered.
For this study, probabilities of each event of this decision analysis were taken
from the published literature (DeLuca et al., 2009; Go et al., 2011; Hibbard et al, 2001:
Hook et al., 1997; Kamath et al., 2009; Landon et al., 2004; Levine et al. 2001; Menacker
et al., 2010; O’Shea et al., 2010; Patel & Jain, 2010; Spong et al., 2007; Yee et al., 2008),
and cost estimates used were derived from HCUPnet (2012) data from 2010. While the
use of national-level cost estimates is a strength of this study, it is possible that some of
the probabilities drawn from the peer-reviewed literature have become outdated over
time. The complications considered in this study’s decision analysis were chosen to
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allow for transparency of key structural assumptions, and are the most common
complications. However, incremental costs for ERCD and TOL for mother and baby
were relatively large, and the finding that TOL has lower cost would likely remain robust
even if the study expanded the pool of complications under consideration.
Although the complications that are used in the decision trees have distinct billing
codes and are billed separately, these probable events do not always occur in isolation. It
is possible that one complication might cause the next and give rise to cascading
complications. Thus, assuming these complications are mutually exclusive and not
accounting for cost-effectiveness probabilities of co-occurrences are limitations of this
analysis.
Limitations due to Physician Idiosyncratic Coding Practices
HCUPnet (2012) used data derived from provider medical coding reported by a
stratified sample of 1,000 hospitals. Not knowing the extent to which providers across
the country use the same medical coding practices is a limitation because it introduces a
possible measurement error, which would decrease the precision of derived estimates.
Individual providers may have idiosyncratic coding practices, and coders may have been
trained to use the same codes but in different ways. As an example, cesarean deliveries
are coded according to whether they are primary or repeat. There is also a code for
second and subsequent cesarean delivery. It is possible that for some providers the
“repeat” cesarean code is routinely used instead of the “second and subsequent” cesarean
code. Additionally, each possible complication for mother and baby is a combination of
ICD-9-CM procedural codes, DRGs and CCSs. Last, it is also unknown whether or not
the complications are all accounted for with codes used by the health-care providers.
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Limitations of Effectiveness Measure (LOS)
Gold et al. (1996) and Rascati (2009) emphasized effectiveness as a measurement
that achieves health improvements and pertains to clinical practice. This study utilized
length of hospital stay as the effectiveness measure because it is measurable, most often a
sign of health improvement, and the HCUPnet (2012) data included LOS along with the
ICD-9-CM codes for each complication. A limitation of using LOS is that it only
accounts for pregnancy complications that occur during a hospitalization. It does not
account for other possible complications that might occur to the mother and baby after
discharge.
Implications
This section will discuss possible implications of this research for practice, policy,
and research. Many of the points raised are based on the limitations listed above.
Implications for Practice
This study’s focus on women’s decision-making about mode of delivery for a
second pregnancy with a previous cesarean has practice implications for issues such as
shared decision-making, education of health professionals, integration of shared decisionmaking into prenatal care, and the relationship between changes in practice and cost to
payers, patients and providers. Each is discussed in the sections to follow.
Shared decision-making. Many studies on shared decision-making focus on the
patient’s perspective. In such cases, shared decision-making has a potential to decrease
the patient’s decisional conflict because the process assists with identifying the patient’s
values, informs the patient of treatment options, and reduces the proportion of patients
that are passive in decision-making. It can also decrease costs. For example, Stacey et
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al. (2011) conducted a Cochrane review with 20,000 participants from 86 randomized
controlled trials. They found that shared decision-making was associated with 25% fewer
major elective invasive surgeries chosen by patients compared to conservative treatment
options.
Integrating teaching models into professional education. Shared decisionmaking can provide students studying to be health professionals in fields such as
medicine, nursing, and pharmacy with several important skills and resources. It can teach
them how to encourage, support, and guide patients with values clarification; inform
them about treatment options; and empower them to make their own decisions. This
approach would be especially useful if taught through interprofessional, collaborative
team-based education, which encourages a broad range of ideas, knowledge, and
perspectives. Team-based education is also important because it prepares students to be
members and leaders of a health-care team that can enhance the quality and outcome of
patient care.
Moreover, teaching shared decision-making with knowledge of how insurance
works, including billing practices, and differentiating types of costs and charges could aid
new and experienced practitioners. With this knowledge, these practitioners would be
able to ask questions about costs and encourage transparency on the part of the payers.
This knowledge could also facilitate the sharing of cost information as part of shared
decision-making.
Shared decision-making and prenatal care. Shared decision-making during
maternity care entails choices specific to prenatal care, delivery, and postpartum and is an
ongoing, interactive process between a woman and her health-care provider. This
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process encompasses coordination of the woman’s and her family’s needs and
preferences, based on evidence that can help them make informed choices.
As part of prenatal care, shared decision-making has been used for genetic testing
options with established decision aids (Informed Medical Decision Foundation, 2011).
Using the genetic testing model for shared decision-making in professional continuing
education could enhance the delivery of maternity care services. By using shared
decision-making as an overall practice model, women in a second pregnancy with a
previous cesarean would be offered their choices in this manner. Stacey et al. (2011), in
their systematic review of 20,000 patients from 86 randomized controlled trials, found
that decisional aids decrease decisional tension and improve communication between
providers and patients, thus creating a safe and respectful environment conducive to
patients’ optimal information processing. Transforming maternity care to use shared
decision-making overall is a multistakeholder effort that could include core competencies
established by professional organizations or regulatory boards, as well as professional
education sessions that offer continuing education credits.
Change in Practice. As this study demonstrated for payers, a TOL is more costeffective than an ERCD for a woman at term in her second pregnancy with a previous
cesarean. A decrease in surgical procedures, such as ERCDs, will lower costs for healthcare payers, which usually means lower costs for patients. The study demonstrates that
increasing the use of TOL could save costs for payers without increasing LOS for the
mothers. It also demonstrates that TOL could substantially decrease LOS for babies.
These savings could give payers an incentive to invest in shared decision-making models
that might increase the use of TOL. However, it will take time for providers to use
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shared decision-making models with patients to decide for ERCD or TOL, if those
models include costs to payers. It might also be difficult for individual practitioners to
accept this as part of their scope of practice and responsibility in maternity care and other
areas.
Nonetheless, given the pervasive concern about health-care costs, if clinicians use
decision aids that include each procedure’s actual cost, it could help the individuals who
(estimated currently at 60%) rely on high patient cost-sharing plans to help defray the
costs of their care; as of 2014 is estimated that in the US, 17.4 million people fall into this
category (American’s Health Insurance Plans, 2014; Panchai, Rae, & Claxton, 2012).
Providers might frame cost as an issue that patients and clinicians “share” and discuss as
part of the growing focus on patient-centered care and patient engagement. This way of
framing cost also means that both clinicians and patients need to see cost as part of their
purview, and providers need to see it as part of their scope of practice. Questions about
inclusion of family members and others on the health-care team as part of this decisionmaking discussion would need to be addressed.
Implications for Policy
Under a reformed health-care system, discussions about shared decision-making,
patient engagement and new types of delivery and payment systems abound. Hence,
discussions of the policy implications of shared decision-making from a payer’s
perspective need to take into consideration the constantly changing context of care, which
includes evolving structures, processes, and outcomes measures. Some of the policy
issues that shared decision-making raises are bundled payments, alternative delivery
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settings that might promote cost savings and facilitate shared decision-making, and health
policy and politics as they pertain to the topics raised in the study.
Bundled payments. Typically, health care is paid for on a fee-for-service or
unit-of-care-delivered basis. The ACA (2010) established the Centers for Medicare and
Medicaid Innovation and authorized one billion dollars to test payment reform models
that include paying for a set of services to treat a given condition or provide a given
treatment as a bundled payment. This single payment to providers or health-care facilities
(or jointly to both) covers all treatments given for that condition. These payments are
made on the basis of the expected cost of a defined clinical episode of care that may
include several practitioner types, settings of care, and services or procedures over a
given period of time. Most pilot studies of bundled payments have been for defined
clinical conditions, including congestive heart failure, total joint replacement, and type 2
diabetes (Catalyst for Payment Reform, 2011). When designing a bundle of care,
consideration for improving value is built in by including clear quality metrics focused on
desired clinical outcomes that providers must achieve to maximize their payments.
With over 4 million women giving birth annually, increased use of bundled
payments for maternity care could yield dramatic cost savings to the overall health-care
system. Prenatal care is at present paid to health-care providers through a “global”
payment system. This system incorporates aspects of “normal” prenatal care—up to 60
days after the birth for the mother—and the provider’s delivery fees. Pediatric providers
bill for the baby’s care separately from care for the mother. Hospitals and birth centers
are also paid a global fee for normal deliveries. Occurrences outside of normal are paid in
a fee-for-service manner.
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Prospectively paying an entity (health plan, provider group, hospital system) for a
normal episode of pregnancy, including prenatal care, baby care, delivery, and 60 days
after the delivery, as a bundled payment could demonstrate cost savings for health care
overall (Catalyst for Payment Reform, 2010). Settling payments after the episode would
require making adjustments to accounts for outliers.
Instituting this policy change has real potential to improve care coordination and
quality, while reducing costs to the health-care system as a whole. Bundling all services
and care given for a maternity episode also has the potential to encourage evidence-based
practices and clear quality metrics, and to focus on desired clinical outcomes, all of which
achieve maximum payment to the health-care providers.
Effective implementation of bundled payment systems relies heavily on setting
optimal reimbursement rates. The Center for Healthcare and Quality Payment Reform
(Center for Healthcare and Quality Payment Reform, 2013) identifies models for
maternity care in Illinois and California as having great potential for innovative payment
reform. Each of these states has instituted a bundled payment model with decreasing cost,
while maintaining or improving quality.
Provisions for alternative delivery settings or structures might promote cost
savings for maternity care. Birth centers, alternative delivery settings, are a safe option
for an out-of-hospital birth and are typically one-fourth the cost of a hospital birth (Center
for Healthcare and Quality Payment Reform, 2013). Only women without any previous
pregnancy complications are low risk enough to deliver in a free-standing birth center. A
woman in her second pregnancy with a previous cesarean, no matter the reason for the
cesarean, is unable to deliver at a birth center.
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Policy Stakeholders. This study’s findings would be of interest to several policy
stakeholders, such as state insurance commissioners, health-care payers (which can vary
by state) and administrative leaders in health-care systems. Bundled payments show the
possibility of decreasing national-level health-care spending by 4.5% (Hussey et al.,
2011). An alternative approach to payment for maternity care would not only save
health-care payers money by bundling care but might improve outcomes by scheduling
fewer ERCDs and encouraging more TOLs. These cost savings might encourage
stakeholders to promote high quality care at a lower cost.
Implications for Research
This next section will identify implications of this study for future research. Major
topics are use of HCUPnet (2012) data, replicating this decision model using one payer,
and establishing a QALY for ERCD and TOL.
Using HCUPnet (2012) data. Using 2010 HCUPnet (2012) data provided an
opportunity to use specific diagnosis and procedure codes to establish costs for ERCD
and TOL for the mother and baby. Additionally, as a free, publicly available project
supported by AHRQ, HCUPnet (2010) provides easy accessibility for researchers. Cost
in this research was a measurement of the amount paid by the health-care payers to
health-care facilities for the care, not necessarily the cost incurred by the health-care
entity to deliver the care. In performing a cost-effectiveness analysis, cost estimates are
necessary. Despite its limitations (discussed previously), using HCUPnet (2012)
summary data to quantify costs for ERCD and TOL for the mother and baby, as in this
study, offers a model for other researchers interested in using national-level estimates.
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The peer-reviewed literature lacked evidence on actual costs of care associated
with the baby for ERCD and TOL. Quantifying the cost of this care could be a potential
future research project. Also, including the cost of care for the mother-baby dyad could
support researchers, health-care decision makers, health-care payers, and health-care
providers with relevant cost data when establishing payment models and plans for care
and when instituting the use of decision aids. When formulating payment models, healthcare payers weigh the pros and cons of available alternatives, taking into account
potential variations in patients and providers, which include costs.
Replication of the decision model with different payers. This research focused
on health-care payers, but not any specific payer, in order to enhance generalizability
across payers. Future research could separate out specific payers using the same
methodology to inform policies under consideration in an entity. The Center for
Medicare and Medicaid Services, for instance, might duplicate this model using only
Medicaid cost estimates with the aim of providing states with estimates that can be used
for bundled payments for normal deliveries.
The addition of reliable cost estimates to, for instance, the VBAC calculator
developed by Grobman et al. (2009) could help extend and disseminate the results of this
study. This tool was designed for educational use with obstetrical providers and women
to predict the probability of successful VBAC. The educational value of this tool and its
use to promote shared decision-making would be enhanced by the inclusion of reliable
cost estimates for TOL and ERCD.
Establishing a QALY for ERCD and TOL. Traditionally, QALYs are used as
the preference-sensitive outcome measure in cost-effectiveness analysis. In this study,
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LOS was the measurable outcome because QALYs have not been established for the
decision between ERCD and TOL. Future research establishing a QALY for ERCD and
TOL for the mother and the baby would strengthen and broaden the cost-effectiveness
analysis in this area.
Conclusion
Healthy People 2020 (2011) set a goal of decreasing repeat cesarean delivery rates
by 10% by 2020. Engaging a woman in shared decision-making to decide between ERCD
and TOL, encouraged by health-care payers, would provide an opportunity to reduce
health-care costs by reducing the rate of elective repeat cesarean deliveries and could
assist with meeting this goal.
Analysis of actual direct cost data from HCUPnet (2012) from the year 2010
indicated the expected cost of an ERCD to be $7,187 for the mother and $8,570 for the
baby, whereas a TOL was $6,388 for the mother and $4,884 for the baby. Using these
findings, decreasing the ERCD rate (502,000 repeat cesarean deliveries in HCUPnet for
2010) by 10% could lower health-care spending by approximately $225 million per year
(mother and baby ERCD total cost – mother and baby TOL total cost)*ERCD rate*.10=
($15,757-$11,272)*502,000*.1=$225,147,000.
The results of this cost-effectiveness analysis demonstrate a TOL to be more costeffective than an ERCD, even knowing that the LOS for the mother is very similar for
both procedures. The most significant finding of this dissertation is how much better a
TOL is in cost and effectiveness for the baby, which has not been previously
demonstrated in the peer-reviewed literature. The probability of a complication is greater
for both the mother and baby with an ERCD than with a TOL. Health-care payers could
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promote reduction of the ERCD rate through changes in the benefit design and payment
models. Providing direct cost estimates for health-care payers could inform national
initiatives to reduce the number of ERCDs, improve the health of mothers and babies,
and reduce costs.
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Average cost-effectiveness ratio – A ratio that compares the cost and effectiveness of a
one treatment.
Cesarean delivery – Extraction of an infant, placenta, and membranes through an
incision in the maternal abdominal and uterine wall.
Decision analysis – Explicit, quantitative, systematic approach to decision-making under
conditions of uncertainty in which probabilities and consequences of each possible event
are explicitly stated.
Dehiscence – The separation of a wound or a surgical scar.
Direct medical costs – Costs of medically related inputs used directly to provide a
treatment (Rascati, 2009).
Dominance – The state in which an intervention being studied is both more effective and
less costly than the alternative.
Elective repeat cesarean delivery – Cesarean delivery for a subsequent pregnancy after
having a cesarean for a previous birth. This is a planned procedure after 39 weeks
gestation.
HCUPnet (2012) – A free, interactive, publicly available, online query system based on
aggregated tables that AHRQ established from the NIS HCUP data.
Health-care payer – An entity responsible for payment of health-care services (Haddix,
Teutsch, & Corso, 2003).
Health-care provider – A health-care professional licensed within medicine or allied
health professional who provides preventative, curative, promotional, or rehabilitative
health care services to individuals, families, or communities.
Hemorrhage – The loss of blood in the post-partum period (after delivery of baby) of
more than 500 ml following a vaginal delivery or 1000 ml following a cesarean delivery
(Begley, Gyte, Devane, McGuire, & Weeks, 2011).
Hysterectomy – Surgical removal of the uterus.
Incremental cost-effectiveness ratio – The ratio of the differences in costs between two
alternatives to the difference in effectiveness of the same two alternatives.
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Indirect medical costs – Costs associated with loss of work or inability to work or
engage in leisure activities after a medical intervention
Informed decision-making – The process by which a “reasoned choice is made by a
reasonable individual using relevant information about the advantages and disadvantages
of all possible courses of action, in accord with that individual’s beliefs” (Bekker et al.,
1999, p. 1).
Length of Stay –Time spent in a hospital, measured from admission to discharge.
Low transverse uterine incision – Most common surgical method for performing a
cesarean delivery; an incision made transversely in the lower segment of the uterus.
Maternal mortality – Death occurring to the mother during childbirth hospital stay.
Neonate death – Death occurring to the baby during childbirth hospital stay.
Nulliparous – Relating to a woman who has not given birth.
One-way sensitivity analysis – Mathematical calculation that isolates one parameter at a
time in a decision analysis to indicate the degree of influence each parameter has on the
outcome of the entire analysis.
Operative injury – Unintended injury during surgery to another organ, muscle, blood
vessel, or tissue surrounding the surgical area.
Placenta acreta – Implantation of the placenta over a uterine scar where the placenta has
grown into the scar tissue.
Placenta previa – Implantation of the placenta at the cervical opening below the baby.
Point of service – Refers to the specific time the health-care service is provided, such as
during a clinic visit.
Quality-adjusted-life-years (QALY) – An outcome measured as life years gained,
adjusted (weighted) by patient preferences for various health states (Rascati, 2009).
Rescue cesarean delivery – A cesarean delivery that is performed when a TOL fails.
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Respiratory distress syndrome – Breathing disorder that affects newborns, usually
developed in the first few hours of life.
Sensitivity analysis – Mathematical calculation that isolates or considers parameters
involved in a decision to indicate the degree of influence each parameter has on the
outcome of the entire analysis. It is used to measure the uncertainty of the probability.
Sepsis – Infection that is life-threatening.
Shared decision-making – A collaborative process that allows patients and their
providers to make health decisions together, considering best scientific evidence as well
as the patient’s preferences and values.
Thromboembolism – Lodgment of a blood clot causing blockage of a vein. There is an
increased chance of thromboembolism in pregnancy due to a hyper-coagulated state.
Deep vein thrombosis (DVT) and pulmonary embolism (PE) are the most named
complications to the veins in pregnancy. Thromboembolism is a rare event.
Trial of labor – The process starting with spontaneous labor for a woman after her first
delivery resulted in a cesarean. The goal is a vaginal delivery after a cesarean.
Uterine rupture – Full thickness disruption of the uterine wall and accompanying
clinical evidence of uterine rupture (from ICD-9-CM).
Utility – In economics, this is a representation of preferences assigned to some set of
goods and services.
Vaginal birth after cesarean – With a previous pregnancy resulting in a cesarean
delivery, the subsequent pregnancy resulted in vaginal delivery.
VBAC rate – Successful VBAC divided by all women with previous cesareans. The
HCUPnet data are stated in number per 1000.
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ERCD

Elective repeat cesarean delivery

VBAC

Vaginal birth after cesarean

TOL

Trial of labor

ACOG

American College of Obstetricians and Gynecologists

RCD

Rescue cesarean delivery
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